Decoding menstrual health across the lifespan: a scoping review on the use of digital health tools to improve women's health and performance

Sarah C Johnson[1,3]*, Johanna O'Day[1]*, Emily Kraus[1,2], Scott Delp[1,3], Jennifer Hicks[1,3]

[1]Wu Tsai Human Performance Alliance, Stanford University
[2]The Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford University
[3]Department of Bioengineering, Stanford University
*Equal Contributors
Corresponding Authors: Dr J Hicks jenhicks@stanford.edu, Dr SC Johnson: scjohns@stanford.edu,

Abstract

Digital health tools provide longitudinal physiological and behavioural data that can address knowledge gaps in women's health. This is particularly relevant for understanding hormone-driven physiological changes and symptoms, which impact health and performance across the lifespan. We conducted a scoping review of research using wearables or smartphone applications to identify insights about physiology, health behaviours, and symptoms throughout the menstrual cycle and menopausal transition. We identified 40 original articles. We summarise findings that reproduce lab-based results, giving confidence in the use of digital health tools for studying menstrual health, along with new insights gained. Given the importance of validation against gold standards, and the lack of a prior synthesis of wearable accuracy for women's health applications, we next report accuracies of wearables that measure biometrics relevant to menstrual health. Finally, we discuss future research needs, including understanding physiological changes during perimenopause, and the role of health behaviours in symptom management.

1. Introduction

Women experience hormonal fluctuations throughout the menstrual cycle and across the lifespan. But there is a lack of knowledge about how to effectively manage associated symptoms and optimise health, athletic performance, and productivity. Between 74 and 90% of women report symptoms, both prior to and during menses, for example mood swings and abdominal bloating or dysmenorrhea (pain during the menstrual cycle)[1–3], with 20 to 40% estimated to experience premenstrual syndrome (PMS)[2]. Furthermore 3 to 8% of women report severe and disabling premenstrual symptoms that meet the criteria for premenstrual dysphoric disorder (PMDD)[2,4].

These symptoms associated with the menstrual cycle can affect quality of life. For example, in a study of over 32,000 women in the Netherlands, 81% reported impaired work performance in the past three months due to the menstrual cycle, and 14% reported absenteeism in the past six

months[5]. Another study found 45% of surveyed women using the Flo app and living in the
United States, reported absenteeism related to the menstrual cycle in the previous twelve
months[6], while in low and middle income countries there was pooled absenteeism of 15%[7]. In
Japan, the estimated annual economic burden due to menstrual symptoms was estimated at 8.6
billion United States Dollars[1]. Across a range of sports, more than 50% of female athletes
reported a negative impact of menstrual and premenstrual symptoms on training and
competition[8–10]. Further, perimenopausal women have 40% higher odds of displaying
depressive symptoms than premenopausal women[11], and consistently show moderately
impaired quality of life[12]. The economic burden due to menopausal transition (perimenopause)
symptoms cost the United States more than $26 billion annually[13].
49
The cyclical changes in hormones are well characterised throughout the menstrual cycle: during
the follicular phase, beginning with menses, increasing concentrations of follicle stimulating
hormone (FSH) stimulate ovarian follicles to secrete estrogen. Once a critical estrogen
threshold is reached, a surge in luteinizing hormone (LH) and a smaller spike in FSH occurs,
triggering ovulation. In the subsequent luteal phase, progesterone is secreted from the corpus
luteum that releases the egg, LH and FSH concentrations decline, and estrogen concentration
remains high. Subsequent decline of progesterone and estrogen triggers menses. The gold
standard for ovulation confirmation is transvaginal ultrasound imaging of follicular release, with
serum testing to confirm the LH surge and progesterone peak as the second preferred choice.
However, LH testing alone (typically in urine) and/or tracking of basal body temperature
increases at ovulation are commonly used as non-invasive measures.
61
The use of hormonal contraception, as well as the menopausal transition, alters endogenous
hormonal profiles in different ways. Many contraceptives involve the exogenous administration
of hormones. For example, combined oral contraceptives release synthetic estrogen and
progesterone systemically, which suppresses endogenous ovarian hormone production[14]. The
hormonal IUD secretes synthetic progestin which acts locally to cause endometrial thinning,
inhibition of sperm motility, and cervical mucus thickening, but may also suppress endogenous
hormones, and inhibit ovulation in some women[15]. During perimenopause, rising FSH
concentrations reflect a declining number of ovarian follicles and responsiveness, resulting in
pronounced estrogen fluctuations before permanent decline[16,17].
71
Findings from lab studies have identified some connections between these hormonal changes in
the menstrual cycle and physiological measures and symptoms. Lab studies have shown that
progesterone consistently elevates core body temperature across various female cohorts[18,19].
This effect, consistent with the observed high progesterone and higher core temperature in the
luteal phase, appears to be reduced by estrogen[20]. During the luteal phase, heart rate also
increases, potentially due to the influence of progesterone and estrogen on the autonomic
nervous system or as a secondary effect of elevated body temperature[21]. Progesterone
increases respiratory function by increasing carbon dioxide sensitivity, breathing rate, and
potentially bronchodilation via smooth muscle relaxation, while evidence of estrogen's
interaction on this effect is contradictory[22,23]. Understanding links between symptoms and
physiology is limited, but several lab-based studies suggest that women with severe

premenstrual symptoms or PMDD often exhibit lower heart rate variability (HRV), indicating
reduced parasympathetic activity, at different times in the menstrual cycle[24–27]. While these
findings are valuable, our knowledge of the relationships between hormones, physiology,
symptoms, and health behaviours is still limited.
87
Advances in digital health tools, including wearable technology and smartphone apps, provide a
unique opportunity to bridge critical knowledge gaps in female health, wellbeing, and
performance by enabling large-scale, continuous, and cost-effective collection of physiological
and behavioural data. In-lab approaches, while valuable, have been limited by sample size and
diversity, measurement frequency, and a lack of accompanying physical activity and sleep data.
Wearables can continuously measure heart rate, HRV, respiratory rate, skin temperature, sleep
metrics, and activity metrics. Independent or associated smartphone apps allow users to record
menses dates, daily symptoms, mental state, as well as activity and behaviour details. Digital
health tools also include apps with non-wearable devices, for instance, temporary smartphone
camera add-ons can be used with an app to provide quantitative readings of hormonal urine test
strips[28].
99
Given the proliferation of digital health tools, there is a need to evaluate how they are being
used in women's health research. It is important to assess their accuracy, the discoveries they
have enabled, and opportunities for future research. Past reviews of digital tools addressing
women's health have focused on identifying unmet needs in software design and hardware
development[29–31], accuracy of predicting ovulation and menses onset for contraception and
conception purposes[30,32–35], and the utility and implementation of technology tailored to monitor
and diagnose conditions prevalent in women[36–38]. We found only one review that summarised
findings from passive monitoring with commercial wearables, but this review focused solely on
trends in thermoregulation relevant to the menstrual cycle[21].
109
No existing reviews summarise findings from digital health tools that concurrently track female-
specific, hormone-induced events such as the menstrual cycle or menopausal transition and
report physiological, behavioural, and symptomatic outputs. Further, no prior review has
systematically evaluated whether digital technology has led to significant new research insights.
There is also a critical need to understand when women's health researchers can trust digital
health tools, which can be assessed by both direct validation compared to gold standard
measures, as well as indirect validation to determine if tools reproduce known relationships from
lab-based studies. While many studies and reviews have evaluated the accuracy of individual
wearable sensors to predict characteristics related to the menstrual cycle (e.g. length, phase),
none have characterised accuracy in the context of women's health research or across multiple
physiological biometrics and behaviours (i.e., resting heart rate, HRV, respiratory rate, skin
temperature, and sleep).
122
We conducted a scoping review of studies that used digital health tools—including mobile
applications, wearable devices, or integrated app-device systems—to characterise changes
associated with female-specific, hormone-driven events such as the menstrual cycle and
menopausal transition. Our review includes menstruating females, individuals using hormonal

contraceptives, and those navigating the menopausal transition. The review excludes findings
regarding pregnancy and postpartum. While we did not exclude studies that included women
with gynecological conditions such as endometriosis or gynecological cancer, these conditions
were not the focus of the review.
131
We first summarise the knowledge gained from digital health studies about the interplay
between physiology, behaviours, symptoms, and hormonally driven processes. We discuss new
insights gained, and compare findings from digital health studies to prior lab-based work. We
then summarise the reported accuracy and resolution of digital health tools to assist researchers
in making informed decisions about device selection and digital health study design. We close
by discussing key unmet research needs in female health, wellbeing, and performance that
could be addressed using digital health tools in order to inspire future research.

2. Results

2.1 Characteristics of included studies

In total, 40 studies were considered eligible for this scoping review based on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews
(PRISMA) process (see Methods). Our search terms related to digital health tools ("digital
health" OR "wearable technology" OR "wearable devices" OR "mobile health" OR "smartphone
application" OR "app") and menstrual health ("ovulation" OR "ovulatory cycle" OR "cycle
tracking"), ("menstrual cycle" OR "menstruation" OR "period tracking") identified 168 original
research articles. We screened the abstracts of all 168 identified articles, screened the full text
of 51 articles, and ultimately included 23 of the identified articles in our review. From the
references of these identified articles and websites, we extracted an additional 43 papers and
included 16 additional articles to bring the total from 23 to 39. Our search for digital health
studies of perimenopause and menopause ("menopaus*" OR "perimenopaus*") resulted in 15
articles for screening, and only four for inclusion, of which only one was unique to the
menopause search, bringing the eligible articles total from 39 to 40. Study cohorts ranged in
size from 10 to 19,000,000 female participants, predominantly aged 18 to 55, but in a few
studies participants were as young as 13 or as old as 90. We summarised reported non-
biometric menstrual characteristics (Table 1; 17 relevant studies) and biometric and behavioural
insights (Table 2; 29 relevant studies) across the menstrual cycle.

2.2 Insight gained into physiology and behaviours accompanying menstruation

Digital health studies have enabled researchers to refine our understanding of how menstrual
cycle physiology varies across lifespan. In this section we summarise the reported
characteristics of menstrual cycles and the limited emerging research that uses the capabilities
of digital health tools to compare menstrual cycle characteristics across demographic groups

and other subpopulations, and to connect physiology and menstrual cycle characteristics with
symptoms, physical activity, and sleep.
166
167 ***2.2.1 Characterising and refining normative trends in menstrual cycle length, menstrual***
168 ***bleed length, and timing of ovulation***
169
Menstrual cycle length and variability
Understanding typical cycle lengths and variability, both within and between women, is crucial to
distinguish natural variability from underlying health concerns[39]. Traditionally, a mean menstrual
cycle length of 28 days with a 21-35 day range has been considered "normal" and was used as
an inclusion criteria in many of the studies[40]. In 2018, the International Federation of
Gynecology and Obstetrics (FIGO) guidelines for the range of cycle lengths were updated to 24-
38 days[40,41]. Across the majority of studies we reviewed, the average "ovulatory" menstrual
cycle determined typically with self-reported LH testing or basal body temperature) was 28-30
days[42–50], while menstrual cycles analysed without any estimate of whether ovulation occurred
averaged 27-30 days[51–57] (Table 1). The standard deviation of menstrual cycle length between
people varied from 2.3-7.2 days and variability within women from cycle to cycle averaged 2.6-
4.4 days. However, these values for average length and variability may not be fully
representative, since studies often excluded conditions that could impact the menstrual cycle
such as hypothyroidism or endometriosis and women with shorter or longer cycles than
"normal". The general agreement in average cycle length between digital health studies and
prior work provides confidence in using digital health technology to track cycle length in large
and free-living populations, but additional studies with broader inclusion criteria are needed to
better characterise the full spectrum of menstrual cycle characteristics.
188
Indeed, three studies, each including over 10,000 women reported that between 8% and 13% of
women had ovulatory menstrual cycle durations outside "normal" ranges (i.e., fewer than 21-24
days or more than 35-38 days), depending on the study, again with ovulation estimated from LH
urine testing or basal body temperature[42–44]. Furthermore, in a study of 378,000 women, 8% of
the women showed median cycle-to-cycle variability of 9 days[51], and three studies reported that
over 19% of women had a greater than 4[50] and 5 day cycle-to-cycle variability[43,44].
195
Meanwhile, women using any type of contraceptive pill that suppresses endogenous hormones
showed no cycle length changes compared to those naturally cycling, (cycle length = 27.7±1.44
days)[52] though this is consistent with a standard 28-day pill regimen. We found one digital
health study analysing bleed intensity in the 3 to 9 months following hormonal IUD insertion and
found that 10% had amenorrhea and 41% had irregular cycles due to spotting (fewer than 8
total days of menstrual bleeding over the 6 months)[58], underscoring the disruption of menstrual
cycle characteristics. Digital health tools are uniquely positioned to validate preliminary evidence
linking progestin dosage to amenorrhea rates[59,60] and to explore dose versus endogenous
hormones patterns via remote urine test logging. Large-scale digital health studies have also
enabled researchers to begin to analyse variations in cycle length and other characteristics
across demographic groups and other subpopulations (see Section 2.2.2), and connect cycle
characteristics with symptoms (see Section 2.2.4).

Menstrual bleed length

Abnormal uterine bleeding can indicate underlying health problems and 4.5-8 days is considered a clinically normal menstrual bleed length[40,41]. The studies we reviewed reported a mean or median 4-5 day menstrual bleed length (Table 1), regardless of whether ovulation was estimated or if cycles with prolonged bleeding (over 7 days) were included. A study of over 1,000 participants comparing women on any type of contraceptive pill to those naturally cycling showed no change in menstrual bleed length (4.36±1.09 days)[52]. Menstrual bleed lengths from digital health studies were within the clinically normal bleed length, giving confidence in self-reporting of menstrual bleed length.

Phase length and ovulation

Accurately identifying ovulation is crucial for planning or avoiding pregnancy. If sufficiently accurate, digital health tools could improve our understanding of normal inter- and intra-individual physiological variation and be applied to guide conception or contraception. Identifying changes in phase length can also help to identify shortened luteal phases that may represent insufficient progesterone production that can impact fertility and/or be an indicator of low energy availability in athletes[61–63]. Data collected with digital health tools show that ovulation may occur later in the cycle than the previously expected day 14[64] and with more variable timing, with one study reporting a 10-day range in ovulation day for women with a 28 day cycle[43]. Five out of the six studies that estimated ovulation and reported the mean, median or mode follicular phase length (Table 1)[43,45–48] reported a longer length of 15-17 days, compared to 13-14 days from lab-based studies[65].

The method of ovulation method detection varied between studies, with two studies reporting ovulation via self-reported LH urine test results[43,44], one study also accepting any type of clinical diagnosis[47], two studies using algorithms based on self-reported basal body temperature and symptoms[46,48], and one study using an algorithm based on self-reported basal body temperature and LH urine test results, where available[45]. The variation between studies in cycle length inclusion criteria, measure of central tendency, and ovulation estimation approach could all contribute to the differences between studies. For instance, the mean follicular phase length ranged from 15 to 17 days while mode ranged from 13 to 15, suggesting a distribution that is skewed by longer cycles. And studies that incorporated LH urine tests or clinical diagnosis tended to estimate slightly shorter follicular phases than those that relied on basal body temperature and other symptom reporting. Greater rigor and consistency of reporting in future studies, along with a careful meta-analysis of prior studies, could help to resolve our understanding of the mean and range of follicular phase length across a range of demographic and other groups. One study utilised an app-integrated device to monitor four hormones, enabling potential future studies to confirm ovulation through the dual detection of LH surges and progesterone[66].

Lab-based studies have reported greater variability in the length of the follicular phase compared to the luteal phase, which suggests that an extended follicular phase may be the primary driver of longer menstrual cycle length[65,67]. Studies using digital health tools support this

finding, with a strong correlation between overall menstrual cycle length and the follicular phase
(r=0.77), but only a weak correlation with luteal phase (r=0.37)[43,45]. Furthermore, in short
menstrual cycles, the follicular to luteal phase ratio stayed constant, but in long ovulatory
menstrual cycles (36-50 days) the follicular phase lengthened by 66% with a minimal luteal
phase increase (5%)[43,45]. The luteal phase length stayed consistent across age groups despite
menstrual cycle length changing with age (see Section 2.2.2), providing additional support for
the concept that ovulation timing drives cycle length[43,44].
259
260 ***2.2.2 Differences in menstrual cycle characteristics across demographic groups and***
261 ***other subpopulations***
262
Age
Studies using self-reported cycle tracking apps (with or without ovulation tests) support prior
findings that menstrual cycle characteristics shift with age. In line with lab-based studies[68], for
individuals from age 18 to 25, digital health studies showed highly variable menstrual cycle
lengths[45,53]. After age 25, cycle length shortened with increasing age due to an estimated
shortening of the follicular phase[44,45,53]. When comparing across the study populations, the
standard deviation for menstrual cycle length remained similar from age 18 to 30, then
increased for individuals over age 30[45] and 40[53,69].
271
Digital health studies have also found new relationships between age of menarche and cycle
length and symptoms. A study using data reported by adolescents in the United States aged 13-
18 who used the Clue app found that mean menstrual cycle length was longer (32.4±6.8 days)
and the odds of highly variable, short, or long cycles was greater in the first year of menarche
compared to six years post menarche[70]. Furthermore, shorter cycles and increased reports of
dysmenorrhea were associated with earlier menarche onset[70].
278
Body Mass Index
BMI is known to impact menstrual cycle characteristics, with low BMI associated with
amenorrhea due to hypothalamic suppression[71]. Changes with high BMI have been mixed in
prior studies. One study found longer cycle lengths in individuals with high BMIs based on a
retrospective review of medical records[72], while another found no change in cycle lengths, but
lower progesterone, LH, and FSH and higher free estrogen in individuals with BMI of 30 and
above[73].
286
Digital health studies have shown that cycle length, cycle length variability, abnormal bleeding,
and absent or infrequent menstrual cycles are increased for both low (under 18.5) and high
(over 25) BMI, though underweight cohorts remain underrepresented (2-9%). Compared to
those with a BMI between 18.5 and 25, those with low BMI showed the highest cycle length
variability[74], reported slightly longer menstrual bleed lengths (0.2 days increase)[45], and longer
cycles[74]. Meanwhile at high BMI, longer cycles[69,74], increased cycle variability[45,69,74], and
increased abnormal uterine bleeding[74,75] were reported in some but not all studies. Some of
these effects were small, for example cycle length increased on average by 0.5 and 1.5 days
with BMI above 25 and 40 respectively[51]. Discrepancies between studies, such as the lack of

change in cycle length in those with high BMI reported by Bull et al.[45], may stem from the
exclusion of anovulatory cycles. In contrast, studies like Itoi et al.[74], that included non-ovulatory
cycles may capture a wider range of hormonal disruptions, revealing more significant
differences. Further, Itoi was able to find an increased incidence of anovulatory cycles in those
with low and high BMI, a finding that warrants further exploration. Together, the larger size of
these digital health studies (e.g., including thousands of individuals with high BMI), along with
the regular collection of cycle length data (in contrast with cycle details reported to a clinician
and stored via medical records) has revealed the valuable new evidence connecting BMI with
cycle characteristics and uncovered trends (such as the connection between cycle variability,
anovulatory cycles, and both low and high BMI) to explore in further research.
306
Race and ethnicity
We found that most studies reviewed did not report ethnicity, and those that did predominantly
included participants from the United States, United Kingdom, and Europe with predominantly
White cohorts. Despite the sparse data, the use of digital health tools has begun to show that
there may be differences in menstrual characteristics across different racial and ethnic groups.
For example, Asian and Hispanic participants reported longer and more variable menstrual
cycles[69], and Black participants showed a 33% higher prevalence of infrequent menses
compared to White non-Hispanic women[75]. There is a clear need for research in more diverse
populations in order to understand when there may be meaningful differences between groups.
316
Other subpopulations
Digital health studies have also identified that cycle lengths can be longer and more variable in
other subpopulations. One study of athletes, which did not exclude participants based on cycle
length, reported a longer mean menstrual cycle length of 35 days with a 12-day standard
deviation, reflecting the increased incidence of menstrual irregularity in athletic cohorts[54]. There
is ample opportunity to examine menstrual cycle characteristics in other groups who may be
exposed to physical or other stressors, including shift workers or those with varying
socioeconomic backgrounds.
325
326 A study of women trying to conceive found that mean cycle length and standard deviation varied
327 dramatically in those with menstrual conditions. Women with polycystic ovary syndrome
328 (PCOS), hypothyroidism, or both conditions reported a mean cycle length of 41, 31, and 76
329 days respectively[76]. This characterisation of cycle-length differences between cohorts could be
330 a first step toward earlier diagnosis or better monitoring.
331
2.2.3 Physiological changes throughout the menstrual cycle
Understanding changes in biometrics such as temperature and heart rate is relevant for a
variety of health and performance applications. For example, characterising subtle temperature
dynamics around ovulation is important because many proprietary algorithms that aim to detect
the fertile window in near real time rely on detecting the well-characterised temperature rise
around ovulation. Resting heart rate, HRV, and respiratory rate can be indicators of fitness,
recovery, and overall wellbeing, while unexplained changes in these biometrics can indicate
illness and stress. Establishing baselines for biometric fluctuations across the cycle and lifespan

can help women understand whether deviations coincide with changes in health or performance
or menstrual cycle irregularities. We found that digital health studies using passive monitoring
with wearable sensors have reproduced known trends for skin temperature, resting heart rate,
and respiratory rate (Figure 1), providing confidence in the technology's utility for studying
deviations from the norm that may accompany behavioural or health changes. The results have
also provided new evidence for HRV fluctuations across the menstrual cycle, improved
resolution (i.e., daily rather than weekly) of physiological patterning across the menstrual cycle,
and quantified how these trends change with age.
348
Skin temperature
Laboratory studies show that core body temperature is 0.3-0.7°C lower in the follicular phase
than the luteal phase[21,77] and that the minimum basal body temperature occurs one or two days
before ovulation, or around day 12-14 for a typical 28-day menstrual cycle[78]. This pattern of
change in temperature is used to predict the fertile window around ovulation which indicates the
start of the luteal phase. We found that studies using wearables (ring, wrist and abdominal
sensor) reported that skin temperature measurements were similarly 0.3-0.5°C lower in the
follicular phase as compared with the luteal phase (Figure 1a)[79–85].
357
The continuous nature of wearable-derived biometrics can capture temperature shifts that may
be missed by the discrete sampling of lab or clinical studies. Data from wearables showed that
skin temperature decreased the most in the first 5 days of the menstrual cycle, in some cases
reaching a minimum as early as day 5 then either stabilising until estimated ovulation[81,85] or
declining slightly until a few days pre-ovulation[83] (Figure 1a). Shilaih et al. found that in 43% of
cases the lowest temperature occurred within the five days prior to ovulation, but in 47% of
cases the lowest temperature occurred earlier[80]. One exception is that Alzueta et al. reported a
minimum temperature at estimated ovulation, but this may be due to a lack of measurements
between day 5 of the cycle and ovulation[84]. Taken together, these studies (Table 2) suggest that
while most temperature decrease occurs by the end of menses, the specific minimum point
before ovulation may vary, although whether due to inter-individual differences, inter-cycle
variability, or study methods is unclear. All studies that separated subsequent early and late
luteal phases found that skin temperature peaked in the late luteal phase[81,84,85].
371
One limitation that could contribute to different results is definitional heterogeneity regarding
phases such as 'pre-menstrual', 'fertile days', or 'ovulatory days', which hinders cross-study
comparison and underscores the need for standardised terminology. Furthermore, in most
studies using wearables and in many lab studies, ovulation was confirmed with LH urine testing
alone. While urinary LH testing has been shown to have high accuracy in detecting LH surges
that trigger ovulation[86], with the development of at-home kits to detect progesterone metabolites
from the subsequent progesterone release upon egg release[66], confirmation of ovulation could
be further improved and the relationship to skin temperature dynamics further validated and
refined.
381
Resting heart rate

Some lab studies reported an increase in heart rate in the mid luteal phase[87,88]; one found no
change across the menstrual cycle[89], and another reported an increase at ovulation only[90],
though all had cohorts on the order of 10s of participants recording heart rates at discrete time
points. Digital health studies use frequent, passive measurement of heart rate, usually during
sleep. While cohort sizes have ranged from smaller pilot groups[84,91] to large-scale population
studies exceeding 10,000 participants[52] they have consistently shown that average resting heart
rate increased from the follicular phase to the luteal phase in naturally cycling women by 2.7-3.9
bpm (Figure 1b)[52,84,85,91–95]. Four of the studies with more granular data found that the largest
change in resting heart rate occurred mid-cycle, specifically in the 5 days leading up to, and
including ovulation when compared to post ovulation. Two studies with nearly 510k participants
additionally report that the amplitude of the change in resting heart rate across the cycle
becomes smaller with age[52,96].
395
Respiratory rate
Digital health studies have shown that respiratory rate changed between 0.3-0.6 breaths per
minute across the menstrual cycle, decreasing from menses to the pre-ovulation days, then
increasing and peaking in the late luteal phase (Figure 1c)[85,95]. This higher luteal phase
respiratory rate is in accordance with past laboratory-based studies showing resting respiratory
rate increased by 0.62 breaths per minute in the luteal phase[97].
402
Heart rate variability (HRV)
A systematic meta-analysis of 37 lab-based studies reported that, despite some contradictory
findings, overall, HRV-associated measures in the follicular phase were significantly higher than
those in the luteal phase[98]. Similarly, digital health studies have consistently found a higher HRV
in the first half of the menstrual cycle (Figure 1d). These studies totaling over 19,000
participants also found that HRV continued to decrease across the second half of the menstrual
cycle, with the lowest HRV in the late luteal phase[52,84,85,94,95]. Digital health studies differed
slightly in their conclusions around the timing of peak HRV. In two studies totaling nearly 14k
participants, Sims et al. found HRV peaked in the early follicular phase (including menses)[95],
while Jasinski et al. reported peak HRV the day after menses (day 5)[52]. In contrast, a smaller
study of nearly 200 women by Goodale reported phase-based differences that only trended
towards significance[85]. Jasinski et al.[52] also found that when using a generalised linear model,
the amplitude of HRV change between phases decreased significantly with age, mirroring their
findings on age-related decline in resting heart rate amplitude. The variation in peak timing
could be due to the accuracy of sensors (see Section 2.4), definition and resolution of menstrual
phases, and also mixed evidence that suggests HRV is affected by psychological health[99].
419
Effects of hormonal contraception on physiology
Use of different types of hormonal contraception can alter the physiological patterns observed
throughout a menstrual cycle, which may influence contraceptive choice, particularly in athletes
who may track their heart rate or women optimising recovery and monitoring their HRV. Small
lab studies (with 10 participants or fewer) have shown use of the combined pill (containing both
estrogen and progestin) suppresses endogenous hormones, which in turn flattens the typical
biphasic temperature and resting heart rate curves by keeping them permanently elevated[100,101].

427
Digital health tools have allowed researchers to begin to characterise these patterns in large
cohorts, in greater detail, and with additional types of hormonal contraception. In one study,
wrist-worn wearable data from over 450 women using the combined pill showed they exhibited a
2 bpm higher average resting heart rate throughout the follicular phase compared to the
naturally cycling women[95]. This elevated heart rate peaked in the late follicular phase at around
59 bpm and then declined through the rest of the cycle (for a total change in magnitude of 1.5
bpm), the inverse of the trend and also over half the range observed in naturally cycling women.
HRV fluctuations were also different in those using the combined contraceptive pill. HRV was
lowest in the late follicular phase, then rose through the remainder of the menstrual cycle. This
is in contrast with the decrease in HRV during the luteal phase in naturally cycling women.
Despite the differences in cardiac biometrics, respiratory rate increased across the menstrual
cycle in combined contraceptive pill users, just as observed in naturally cycling women. A
second study with a larger cohort of over 3000 women taking any type of contraceptive pill
similarly showed less fluctuation in resting heart rate and HRV across the menstrual cycle
compared to naturally cycling women (a range of 0.28 vs 2.73 bpm, and 0.51 vs 4.65 ms,
respectively)[52]. A separate cohort of the first study focused on over 250 women using progestin-
only contraception (either oral or intrauterine), showed overall similar trends in HRV, respiratory
rate, and resting heart rate to naturally cycling women[95]. In the luteal phase, HRV was slightly
elevated and both HRV and respiratory rate returned to baseline levels more slowly. We did not
find any studies that reported biometrics for women using specifically hormonal intrauterine
devices or other hormonal forms of birth control.
449
The lack of delineation in several of these studies between combined pill, progestin-only pill,
and hormonal IUD users limits our ability to synthesise and interpret the results and is important
to address in future studies. There is a clear demand for women to know what the different
effects, if any, that each type of contraceptive has on biometrics and menstrual-related
symptoms. The impact of contraceptives on biometrics is particularly interesting as the
combined pill can be prescribed to 'even out' hormonal fluctuations in women with PMDD yet
there remains a lack of studies that have examined the direct impact of contraception on both
biometrics and menstrual or premenstrual symptoms—a gap that digital health tools have the
potential to fill.
459
460 ### 2.2.4 Linking physiology and symptoms across the menstrual cycle
461
Identifying associations between biometrics and menstrual-related symptoms could increase our
understanding of why symptoms occur and aid in both designing and testing the efficacy of
interventions. In lab studies using electrocardiograms each with fewer than 70 women, results
are mixed. Lower HRV was reported in women with the most severe premenstrual symptoms
during the late luteal[25,26], luteal phase[24], the follicular phase[27], or across the cycle compared to
controls[25], while one study reported a lack of reduction in the midluteal phase compared to
controls[102]. There is limited research using digital health tools that assess symptoms and
physiology together. However, initial studies with more than a hundred participants, have
shown, that HRV was inversely associated with self-reported symptoms in women who met the

definition of PMS or PMDD[103] and with a decline in premenstrual mood symptoms[104],

highlighting the benefit of easier access to larger cohorts.

Changes in menstrual cycle characteristics have also been associated with both symptoms and

biometrics. A study assessing 5 million self-reported menstrual cycles found that a cohort of

women with consistently high menstrual cycle length variability were more likely to report

negative symptoms, specifically heavier bleeds and increased likelihood of tracking headaches

and breast tenderness[51]. Another study using a wrist-worn wearable showed that while both

women with irregular and regular menstrual cycles experienced elevated resting heart rate

during the ovulatory phase compared to the menstrual phase, the increase in resting heart rate

was somewhat smaller in women with irregular menstrual cycles (1.8 bpm) compared to regular

menstrual cycles (2.1 bpm)[92]. These initial links between symptoms, menstrual cycle

characteristics, and biometrics suggest that digital tools could be a future avenue to screen for

and monitor conditions such as PMS and PMDD, but much more work is needed to validate

whether the changes measured by wearables correspond to hormonal profiles measured with

gold-standard approaches.

2.2.5 Sleep and physical activity across the menstrual cycle

Understanding how sleep and physical activity can interact with the menstrual cycle is of interest

for health and performance, but few studies exist to-date. Although some women self-report

sleep disturbances[105,106], most studies using polysomnography (an in-lab test that records brain

waves and movement) showed little to no change in sleep measures[107]. Only one study in our

scoping review assessed sleep with a commercial wearable (a smart ring) across the entire

menstrual cycle, revealing that sleep efficiency was marginally lower in the mid-luteal phase

compared to menses[84]. This effect, from a study of fewer than 20 women, was consistent with

another including over 160 women aged 48 to 59, where sleep efficiency declined over the

cycle, plunging in the premenstrual week, as estimated from movement-sensing actigraphy[108].

Taken together, digital health tools have only been able to detect small changes in sleep

efficiency across the menstrual cycle, which is perhaps unsurprising with the still limited

accuracy of sleep metrics from wearable devices (see Section 2.4.1), and the undetermined

relationships between sleep and reproductive hormones[109]. The three sleep studies reported

had cohorts consisting of between 19 and 163 women highlighting an opportunity for insight into

relationships between sleep, menstrual cycle, and biometrics from large-scale sleep studies with

wearable devices. Furthermore, we did not find any studies assessing the impact of physical

activity on biometrics or menstrual cycle characteristics, an open and key area to improve

understanding of how behaviour impacts menstrual health.

2.3 Insight gained into physiology and behaviours accompanying

perimenopause

Overall we found scant passively recorded biometric or behavioural data during perimenopause

and limited data regarding change in menstrual cycle characteristics. This is in part because

many of the digital health studies we reviewed set inclusion criteria for menstrual cycle regularity

that removed the irregular cycles that occur around perimenopause. The studies we found
showed that cycle length increased and cycle variability dramatically increased with age[51,53]. Li
et al found that compared to 35-39 year olds, cycle variability increased by 46% in a 45-49 year-
old-age group and by 200% at age 51-55[51]. Furthermore, Cunningham reported that over half of
women reported irregular menstrual cycles by age 51-55[53].
518
Markovic et al., who included participants aged 19 to 90 without exclusions based on cycle
length or age, found that perimenopausal and menstruating participants had a higher skin
temperature than the non-menstruating group (which included 577 postmenopausal women, 2
pregnant, and 223 non-menstruating females)[48]. The menstruating participants also had a
higher respiratory rate than the non-menstruating participants. Finally, Costeira et al. developed
an app to investigate the role of estrogen, which is considered to be immune stimulatory, in
COVID protection and found that premenopausal women, especially those using contraceptive
pills, exhibited higher COVID protection compared to postmenopausal women[110]. However, the
same protective effect of estrogen was not seen in postmenopausal women on hormone
replacement therapy[110]. Thus, the menopausal transition is ripe with opportunity to better
understand how ovarian hormones relate to changing biometrics.

2.4 Guide to wearables, measured metrics, and associated accuracy

Our literature review revealed good agreement between digital health and lab-based studies,
supporting the use of wearables and apps to study menstrual cycle physiology, but continued
validation against "gold-standard" techniques is needed. To guide researchers in selecting
devices with sufficient accuracy to capture changes in biometrics associated with the menstrual
cycle, the following sections summarise studies that directly compare wearables to gold-
standard measurement approaches, where available (Table 3). We searched PubMed, Web of
Science, Google Scholar, and company websites for studies and public data regarding the
accuracy and precision of the commercial wearables used in the digital health studies we found
in our scoping review. This included the Oura Ring, WHOOP wristband, Ava bracelet, Garmin
watch, Apple Watch, Huawei Band 5, and Fitbit wristband. We provide the reported accuracy of
skin temperature, resting heart rate, respiratory rate, HRV, and sleep metrics. To understand
the accuracy of wearable devices in capturing physical activity throughout the day we refer
readers to prior reviews[111–113].
544
545   ***2.4.1 Skin temperature***
546
Many wearables now passively monitor skin temperature using negative temperature coefficient
sensors that contain semiconductive materials that decrease their resistance with increasing
temperature. Lab-based studies show a body temperature change of 0.3-0.7°C across the
menstrual cycle[21,77] and 1.1°C during perimenopausal hot flushes, based on the gold-standard
rectal thermometer[114,115]. While reported accuracy compared to core body temperature across
all wearables is lacking (Table 3), an in-house study of the Oura Ring demonstrated a high
correlation (r^2 >0.92), including an accuracy of 0.36°C and precision of 0.13°C when compared
to skin temperature measured with i-Button monitors[116]. The i-Button is a research-grade

wireless semiconductor skin-temperature sensor[117] also used as a standard in some validation
studies. Comparison of skin temperature immediately after wake measured with an Oura Ring
versus oral temperature showed a correlation of r=0.56[79]. These results suggest that the Oura
Ring is likely sufficiently accurate to capture changes in temperature across the menstrual cycle
and in response to hot flushes. But researchers must keep in mind that skin temperature is
known to systematically present around 2°C lower than[118], and out of phase[119] with core body
temperature changes. BMI can also impact the absolute value of recordings due to insulation
with visceral fat, although magnitude of change is unaffected[80].

2.4.2 Resting heart rate

Wearables use photoplethysmography sensors that detect minor variations in the intensity of
light transmitted through the skin to estimate changes in blood flow and cardiac activity. Studies
using gold-standard electrocardiograms (ECGs) have shown that resting heart rate increases by
2.3 to 3 bpm between the follicular and the luteal phase of the menstrual cycle[88,120] while
changes during menopause are unknown. In one externally conducted study, six devices (Apple
Watch S6, Garmin Forerunner 245 Music, Polar Vantage V, Oura Ring 2.0, WHOOP 3.0, and
Somfit) were tested overnight in 53 participants. Compared to ECG, the WHOOP 3.0 device
demonstrated the highest intraclass correlation of 0.99 for nocturnal heart rate and lowest
average over-estimation bias of 0.7±0.8 bpm[121]. Most devices with nocturnal recordings
available reported a good intraclass correlation above 0.85 and low bias of less than 2.6 bpm
(Table 3), with the exception being a 0.65 intraclass correlation reported with Somfit, which is a
head-worn sensor and was not used in any of the studies we reported. The Oura Ring 2.0
showed an intraclass correlation of 0.85 and overestimation bias of 1.8bpm, but an Oura-
sponsored[122] and an in-house study[123] reported higher r^2 values of 0.99 and smaller mean
biases of -0.63.

Together, these results suggest that many of the commercially available ring and wrist-worn
devices are sufficiently accurate to measure changes in resting heart rate across the menstrual
cycle, but there are considerations to keep in mind. For example, discrepancies in data
resolution and sampling windows (e.g., raw versus summary data) can hinder comparison
between devices. Specifically, the Garmin devices provided pre-sleep instead of nocturnal
cardiac data, which may have contributed to reported lower accuracy as it may not have
captured a true resting heart rate[121].

There is some evidence that photoplethysmography-measured heart rate can be influenced by
BMI[124] and skin tone[125], but the temporal location of the peaks used to detect heart rate
remained stable. A study using Garmin devices during rest and activity found that ECG- and
PPG-measured heart rates only significantly differed during a transition from rest to activity[126].
Taken together, the evidence to-date indicates that measures of resting heart rate may be fairly
robust across these demographic characteristics with scope for further validation and
improvement.

2.4.3 Respiratory rate

599
Wearable devices estimate respiratory rate using small photoplethysmography sensors on the
skin that detect the high-frequency variations in heart rate linked to respiratory cycles, a feature
called respiratory sinus arrhythmia. In the laboratory, respiratory rate during sleep is measured
with belts that sense chest wall motion or with respiratory inductive plethysmography where
coils of wire are placed around the chest and abdomen[127]. Studies using this approach show
that respiratory rate changes across the menstrual cycle range from 0.63 to 2 breaths/min[97,128].
We found limited data on wearable accuracy for respiratory rate (Table 3). One external study
funded by a grant from WHOOP reported no significant difference between recordings with
WHOOP 2.0 and respiratory inductive plethysmography (15.7±1.7 versus 15.6±1.7 breaths/min,
respectively), with a mean bias of 0.1 breaths/min (1.8%) and a precision bias of 1.0
breaths/min (6.7%)[129], providing some confidence in using photoplethysmography on a wrist-
worn device to measure changes in respiratory rate related to the menstrual cycle, with
additional validation needed for larger and diverse cohorts and for other wearables.
613
614   *2.4.4 Heart rate variability (HRV)*
615
Wearables estimate HRV using heart rate recordings from the photoplethysmography sensor.
In-lab studies use electrocardiograms to record individual heart beats then calculate the
variability in heart beat timing, most commonly using root mean square of successive
differences (RMSSD) between the interbeat intervals over a sleep or rest period, reported in
milliseconds or log-transformed values. A meta-analysis of 37 in-lab studies indicated a
significant overall decrease in cardiac vagal activity from the follicular to the luteal phase, but
only 2 of 8 studies reported a significant difference in RMSSD in the range of 9-20 ms[98,130,131].
The comparative study of Miller et al. found that the WHOOP 3.0 device demonstrated the
highest HRV estimation accuracy compared to ECG measures, with a bias of -4.5±3.9 ms with a
0.99 intraclass correlation[121]. An external study funded by an Oura grant reported a 0.98 r^2
value and -1.2ms bias when compared to ECG measurements[122], which is an improved
performance from the 0.85 intraclass correlation reported in the six device comparative study[121].
These results indicate researchers should be aware of underestimation bias according to their
device, as underestimation could be up to 50% of the variability seen across the menstrual
cycle.
631
632   *2.4.5 Sleep*
633
Detection of sleep using commercial wearable devices typically uses a combination of cardiac
metrics such as resting heart rate, HRV, respiratory rate, and movement metrics in proprietary
sleep-detection algorithms, while polysomnography is the gold standard for measuring sleep in
a laboratory[127]. The comparative study of six wearables found that all could perform the binary
classification of sleep vs. wake periods throughout the night with relatively high accuracy (above
85%) compared to polysomnography. However, the accuracy in estimating total sleep duration
varied widely, with mean errors on the order of one minute overestimation for the Oura Ring and
Polar watch, and 40 minutes or more for the Apple Watch and Garmin watch. All six devices
showed low accuracy in identifying the sleep stages (e.g., slow-wave sleep versus rapid eye

movement (REM) sleep), reporting less than 65% agreement with polysomnography[121]. Several
other external studies show that commercial wearable devices tend to overestimate sleep
duration. Sleep duration was overestimated by 15 minutes with the Oura Ring[132], by 56 minutes
with the Fitbit[133], and 11 minutes with the Ava bracelet)[134]. Taken together, sleep stage
estimation is inaccurate across ring and wrist-worn devices, while researchers prioritising
estimated total sleep accuracy should be aware of the variation in accuracy across devices and
choose devices accordingly.

3. Discussion

651
This scoping review reveals several promising contributions of digital health studies to
understanding of the interplay between physiology, behaviours, symptoms, and hormonally-
driven processes including the menstrual cycle and menopausal transition. Studies using digital
health tools have begun to establish detailed, normative biometric data across the menstrual
cycle. For example, while skin temperature is often used to estimate fertile windows, we found
that digital health studies indicate that the largest decrease in skin temperature, and in some
cases, the minimum temperature can occur as early as day five of the menstrual cycle, unlike
the 1-2 days before ovulation reported by lab studies. This knowledge could improve the
efficacy of wearable-based tools for contraception or conception. Digital health studies have
also provided additional evidence to support fluctuations in resting heart rate and HRV across
the menstrual cycle, and discovered a decrease in the magnitude of this fluctuation with age.
Understanding these changes across the lifespan can help women set realistic training and
recovery expectations. In addition, digital health tools have begun to address how biometric
changes are connected to hormone-related symptoms. For instance, studies using data from
wearables found an inverse association with HRV and symptoms (both affective and
physiological) in women with self-reported premenstrual disorder symptoms. This information is
needed for quantifying the effectiveness of symptom-reducing interventions.
669
Despite new data from digital health studies to characterise normative trends, our review of
studies to-date reveals a need to better understand deviations from the norm, both within and
between individuals. In some cases, whole cohorts have been omitted from most research. For
example, most of the research we reviewed was carried out in predominantly White cohorts and
in the United States, United Kingdom, and Scandinavian countries, which limits our
understanding of the relationships between race, ethnicity, and menstrual cycle physiology.
Perimenopausal women were often omitted from studies, so characterisation of normal
hormonal fluctuations and physiological change during perimenopause is lacking. This is
reflected by the fact that fewer than 1 in 10 women in the United Kingdom feel that they have
received sufficient advice on what to expect during perimenopause[135], with similar trends in the
United States, where 64% of adult women reported a need for more doctors specialising in
menopause[136]. Furthermore, we found that many studies focused on regularly menstruating
women, often only including analysis of cycles with estimated ovulation, and excluding women
with conditions impacting menstruation or using hormonal contraceptives. Menstrual conditions
are common; endometriosis affects 10% of women and many women are undiagnosed for

years[137,138]. Although some atypical menstrual cycles may present no health concerns,
identifying and understanding the causes of irregularity and anovulation and their biometric
connections becomes crucial for better diagnostics and monitoring intervention efficacy. The
relative accessibility and lower cost of digital health tools compared to lab-based approaches
offers promise to including these under-studied cohorts in research.
690
Future digital health studies should concurrently measure hormones, biometrics, and menstrual-
associated symptoms. While we expected to find many studies exploring relationships between
these measures, studies to-date were few. For example, the physiological impact of hormonal
contraception, including effects on cardiovascular biometrics associated with athletic
performance remains under-characterised. For female athletes striving for peak performance,
even small physiological changes may be significant, yet women are often left to use trial and
error approaches when selecting contraception. Furthermore, we need to understand the timing
and characteristics of the transition to a natural hormone cycle after individuals discontinue
using hormonal contraception[139]. Using wearables could help to characterise these effects and
contribute to informed contraceptive choices, but studies have not yet explored these
relationships. Further, the connections between symptoms, biometrics, and hormonal
fluctuations in the menopausal transition is markedly understudied.
703
Digital health tools can help quantify how behaviour and physical or social environment may
influence hormones and physiology, enabling the development of guidelines to manage
symptoms and optimise performance, but again, we found few studies that have explored these
areas. For example, future digital health studies could examine whether altering sleep in the
luteal phase could mitigate premenstrual symptoms, or quantify the relationships between
physical activity and the menstrual cycle, bringing much-needed evidence to guide the popular
trend of "cycle syncing". By understanding how behaviours such as sleep and exercise can
mitigate or exacerbate symptoms related to the menstrual cycle or perimenopause, women
could be empowered to manage their health and performance more effectively. Wearables
could also serve as intervention tools. For instance, in a pilot study, a mobile app providing HRV
biofeedback training showed promise in reducing premenstrual anxiety, stress, and poor
sleep[140].
716
We found that most commercial wearables used in the studies we reviewed had sufficient
accuracy to capture changes in heart rate, respiratory rate, and to a lesser degree HRV. While
sensors that measure skin temperature appear sufficiently accurate to capture changes across
the menstrual cycle, this is based on only one study. Results for accuracy of sleep duration
were device-dependent, and other sleep characteristics (like sleep staging), should be used with
caution. The superior accuracy for cardiac biometrics likely reflects technological maturity of
sensors and extensive validation history compared to more recently integrated features like
sleep and skin temperature, suggesting accuracy will likely improve as hardware and signal
processing algorithms evolve. The reported accuracies mirror the consistency of the findings in
Section 2.2, highlighting how improvements in sensor technology combined with access to
continuous monitoring in large cohorts enables higher resolution data and statistical power that
can clarify mixed reports and reveal new insights. Additional research is still needed to validate

accuracy of wearables in cohorts with diverse characteristics (e.g., BMI, skin color, and
presence of tattoos), given the limited research to-date in this area. Furthermore, retrospective
studies using passively collected wearable data may contain self-selection bias as individuals
who purchase fitness tracking wearables may be more active, of a higher socioeconomic status,
and more health conscious than average. However, providing wearable devices to participants
and intentionally recruiting diverse populations can help to mitigate this bias.
735
Researchers selecting digital health tools must consider their cohort, research question, and the
limitations of each tool. For instance, self-reports cannot confirm if a menstrual cycle is truly
absent or due to a lapse in reporting of menses onset. While biometric data can be used to
predict menstrual cycle and/or ovulation occurrence with good accuracy, ovulation can
sometimes occur without the typical biometric pattern changes and vice versa. A study of
endurance runners may require a device with long battery life that measures heart rate and
distance with high accuracy and resolution during activity only, while a study focused on
recovery may require capturing accurate nocturnal cardiac and sleep parameters with constant
daily activity monitoring. As the wearables we reviewed are wrist or finger-worn, it is important to
note that devices using 2-electrode chest straps[141] and upper-arm-photoplethysmography
sensors can be more accurate than wrist-worn devices[142] for measuring heart rate during
activity.
748
As technology continues to improve, we hope for the development of new tools to monitor
hormones, physiology, and behaviour alongside consistent protocols and safe practices.
Continuous and minimally invasive monitoring of biomarkers, such as hormones via sweat or
interstitial fluid hold promise. Such monitoring could provide insights into normal, optimal, and
pathological states, ultimately guiding more effective management of symptoms and health. As
research in this field grows, it is important for researchers to establish and use standardised
methodologies (e.g., measuring HRV during consistent sleep periods—such as the final hour
before wake—versus varying times throughout the day) and data reporting (e.g., consistent
HRV metrics). With the increasing use and development of digital health tools in women's health
research, there is also a vital need to address privacy concerns, particularly given the legal
complexities surrounding pregnancy termination. Careful consideration must be given to
research planning, data handling, and privacy, as discussed in detail elsewhere[143], including
specific considerations for female health data and privacy analyses of existing apps[144,145].
762
Digital health research offers promise in improving our understanding of the interaction of
physiology, behaviour, and symptoms during the menstrual cycle and perimenopause. The use
of digital health tools in female health is often focused on pregnancy prevention and fertility. By
facilitating characterisation of healthy menstrual cycle norms across a more diverse group of
women, digital health tools can enable understanding of healthy norms and identify when
medical evaluation is warranted. Furthermore, integration of biometric monitoring with
underlying hormone fluctuations, symptoms, and health behaviours can help to identify targets
to monitor interventions and develop healthy biometric ranges. Not only is this understanding a
vital first step toward developing effective solutions, but it also empowers women to take
ownership of their health and enhance their quality of life.

4. Methods

4.1 Literature search

Our scoping review adhered to the recommendations outlined in the PRISMA guidelines
(https://www.prisma-statement.org/scoping). We searched for articles on Google Scholar, Web
of Science Core Collection, and PubMed through December 18, 2025 with the terms ("digital
health" OR "wearable technology" OR "wearable devices" OR "mobile health" OR "smartphone
application" OR "app") AND ("scientific" OR "research outcomes" OR "insights" OR "study
results" OR "clinical research"). We combined these digital health terms first with ("menstrual
cycle" OR "menstruation" OR "period tracking"), and then with ("ovulation" OR "ovulatory cycle"
OR "cycle tracking").
784
We removed duplicates, then two authors (S.J. and J.O.) independently reviewed titles,
abstracts, and keywords of all the retrieved articles. Any disagreements regarding study
eligibility were resolved through discussion and consensus between the two reviewers. Articles
were included if they (i) were written in English; (ii) involved human participants; (iii) used
wearable devices or mobile health apps; (iv) analysed female health physiology or biometrics;
and (v) provided quantitative data collected with digital health tools. We excluded dissertations,
theses, conference proceedings, conference abstracts, and reviews. We excluded articles that
did not include menstrual tracking with a digital health tool and/or articles where longitudinal
data concurrent with menstrual tracking was not reported (Figure 1). We excluded reviews as
primary articles, but reviewed reference lists to identify any additional papers that met our
criteria. We repeated the process replacing the first grouping of search terms with "menopaus*
OR perimenopaus*".

4.2 Outcome extraction

798 We extracted the following outcomes from the included articles: scientific insights on female
799 health with regard to menstruation and menopause; how menstrual cycle phase was determined
800 (e.g., self report or hormonal testing); and study details including number of participants,
801 menstrual cycles, participant demographics (age, BMI, ethnicity), and the digital health tool(s)
802 used in the study.
803

5. Data availability

805 No datasets were generated during the current study. This manuscript is based on publicly
806 available medical literature and references. All sources are cited within the manuscript.

Contributions

SCJ, JO, and JH conceived and defined the scope of the review and wrote the manuscript. SCJ and JO carried out the scoping review search and interpreted, collated and processed the data. SCJ, JO, EK, SD, and JH reviewed, edited, and approved the final manuscript.

Competing interests

The authors declare no competing interests.

6. Acknowledgements

This study was funded by the Wu Tsai Human Performance Alliance at Stanford University and the Joe and Clara Tsai Foundation, as well as the National Institutes of Health through Grant P41EB027060. The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript. We thank Dr Alex Gonzalez for his contribution to early conception.

7. References

1. Tanaka, E. et al. Burden of menstrual symptoms in Japanese women: results from a survey-based study. *J. Med. Econ.* **16,** 1255–1266 (2013).

2. Rapkin, A. J. & Winer, S. A. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. *Expert Rev. Pharmacoecon. Outcomes Res.* **9,** 157–170 (2009).

3. Bruinvels, G. et al. Prevalence and frequency of menstrual cycle symptoms are associated with availability to train and compete: a study of 6812 exercising women recruited using the Strava exercise app. *Br. J. Sports Med.* **55,** 438–443 (2021).

4. Halbreich, U., Borenstein, J., Pearlstein, T. & Kahn, L. S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). *Psychoneuroendocrinology* **28 Suppl 3,** 1–23 (2003).

5. Schoep, M. E. et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. *BMJ Open* **9,** e026186; 10.1136/bmjopen-2018-026186 (2019).

6. Ponzo, S. et al. Menstrual cycle-associated symptoms and workplace productivity in US employees: A cross-sectional survey of users of the Flo mobile phone app. *Digit. Health* **8**; 10.1177/20552076221145852 (2022).

7. Starr, M. et al. Epidemiology of menstrual-related absenteeism in 44 low-income and middle-income countries: a cross-sectional analysis of Multiple Indicator Cluster Surveys. *Lancet Glob. Health* **13,** e285–e297 (2025).

8. Solli, G. S., Sandbakk, S. B., Noordhof, D. A., Ihalainen, J. K. & Sandbakk, Ø. Changes in self-reported physical fitness, performance, and side effects across the phases of the menstrual cycle among competitive endurance athletes. *Int. J. Sports Physiol. Perform.* **15,** 1324–1333 (2020).

9. Armour, M., Parry, K. A., Steel, K. & Smith, C. A. Australian female athlete perceptions of the challenges associated with training and competing when menstrual symptoms are present. *Int. J. Sports Sci. Coach.* **15,** 316–323 (2020).

10. Findlay, R. J., Macrae, E. H. R., Whyte, I. Y., Easton, C. & Forrest Née Whyte, L. J. How the menstrual cycle and menstruation affect sporting performance: experiences and perceptions of elite female rugby players. *Br. J. Sports Med.* **54,** 1108–1113 (2020).

11. Badawy, Y., Spector, A., Li, Z. & Desai, R. The risk of depression in the menopausal stages: A systematic review and meta-analysis. *J. Affect. Disord.* **357,** 126–133 (2024).

12. Coronado, P. J. et al. Quality of life at peri- and postmenopause: analysis of the results from app 'Mi Menopausia'. *Maturitas* **197,** 108267 (2025).

13. Faubion, S. S. et al. Impact of Menopause Symptoms on Women in the Workplace. *Mayo Clin. Proc.* **98,** 833–845 (2023).

14. Rodriguez, L. A., Casey, E., Crossley, E., Williams, N. & Dhaher, Y. Y. The hormonal profile in women using combined monophasic oral contraceptive pills varies across the pill cycle: a temporal analysis of serum endogenous and exogenous hormones

using liquid chromatography with tandem mass spectroscopy. *Am. J. Physiol. Endocrinol.*
Metab. **327,** E121–E133 (2024).

15.   Stanford, J. B. & Mikolajczyk, R. T. Mechanisms of action of intrauterine devices:
update and estimation of postfertilization effects. *Am. J. Obstet. Gynecol.* **187,** 1699–1708
(2002).

16.   Burger, H. The menopausal transition--endocrinology. *J. Sex. Med.* **5**, 2266–
2273 (2008).

17.   Hale, G. E., Robertson, D. M. & Burger, H. G. The perimenopausal woman:
endocrinology and management. *J. Steroid Biochem. Mol. Biol.* **142,** 121–131 (2014).

18.   Forman, R. G., Chapman, M. C. & Steptoe, P. C. The effect of endogenous
progesterone on basal body temperature in stimulated ovarian cycles. *Hum. Reprod.* **2,**
631–634 (1987).

19.   Israel, L. S. & Schneller, O. The thermogenic property of progesterone. *Obstet.*
Gynecol. Surv. **5,** 532–533 (1950).

20.   Stachenfeld, N. S., Silva, C. & Keefe, D. L. Estrogen modifies the temperature
effects of progesterone. *J. Appl. Physiol. (1985)* **88,** 1643–1649 (2000).

21.   Baker, F. C., Siboza, F. & Fuller, A. Temperature regulation in women: Effects of
the menstrual cycle. *Temperature (Austin)* **7,** 226–262 (2020).

22.   Behan, M. & Wenninger, J. M. Sex steroidal hormones and respiratory control.
Respir. Physiol. Neurobiol. **164**, 213–221 (2008).

23.   Haggerty, C. L., Ness, R. B., Kelsey, S. & Waterer, G. W. The impact of estrogen
and progesterone on asthma. *Ann. Allergy Asthma Immunol.* **90,** 284–91; quiz 291–3, 347
(2003).

24.   Blaser, B. L., Weymar, M. & Wendt, J. Premenstrual syndrome is associated with
differences in heart rate variability and attentional control throughout the menstrual cycle: A
pilot study. *Int. J. Psychophysiol.* **204,** 112374 (2024).

25.   Matsumoto, T., Ushiroyama, T., Kimura, T., Hayashi, T. & Moritani, T. Altered
autonomic nervous system activity as a potential etiological factor of premenstrual
syndrome and premenstrual dysphoric disorder. *Biopsychosoc. Med.* **1,** 24 (2007).

26.   Baker, F. C., Colrain, I. M. & Trinder, J. Reduced parasympathetic activity during
sleep in the symptomatic phase of severe premenstrual syndrome. *J. Psychosom. Res.* **65,**
13–22 (2008).

27.   Landén, M. et al. Heart rate variability in premenstrual dysphoric disorder.
Psychoneuroendocrinology **29,** 733–740 (2004).

28.   Pattnaik, S., Das, D. & Venkatesan, V. A. Validation of urinary reproductive
hormone measurements using a novel smartphone connected reader. *Sci. Rep.* **13,** 9227;
10.1038/s41598-023-36539-w (2023).

29.   Pichon, A., Jackman, K. B., Winkler, I. T., Bobel, C. & Elhadad, N. The
messiness of the menstruator: assessing personas and functionalities of menstrual tracking
apps. *J. Am. Med. Inform. Assoc.* **29,** 385–399 (2022).

30.   Zvarikova, K., Machova, V. & Pera, A. Menstrual cycle tracking apps, fertility and
reproductive data, and mobile health care management. *J. Res. Gend. Stud.* **12,** 84 (2022).

31.   Schantz, J. S., Fernandez, C. S. P. & Anne Marie, Z. J. Menstrual cycle tracking
applications and the potential for epidemiological research: a comprehensive review of the

literature. *Curr. Epidemiol. Rep.* **8,** 9–19 (2021).

32.   Lyzwinski, L., Elgendi, M. & Menon, C. Innovative approaches to menstruation and fertility tracking using wearable reproductive health technology: systematic review. *J. Med. Internet Res.* **26,** e45139; 10.2196/45139 (2024).

33.   Kalampalikis, A., Chatziioannou, S. S., Protopapas, A., Gerakini, A. M. & Michala, L. mHealth and its application in menstrual related issues: a systematic review. *Eur. J. Contracept. Reprod. Health Care* **27,** 53–60; 10.1080/13625187.2021.1980873 (2022).

34.   Saugar, E. E. et al. Factors used by mobile applications to predict female fertility status and their reported effectiveness: A scoping review. *Cureus* **15,** e48847; 10.7759/cureus.48847 (2023).

35.   Rabe, I. & Ehlers, J. P. Reliability of Cycle Applications for Pregnancy Planning and Contraception: A Systematic Review. *Mayo Clin. Proc. Digit. Health* **3,** 100239; 10.1016/j.mcpdig.2025.100239 (2025).

36.   Huhn, S. et al. The impact of wearable technologies in health research: scoping review. *JMIR Mhealth Uhealth* **10,** e34384; 10.2196/34384 (2022).

37.   Fitzpatrick, M. B. & Thakor, A. S. Advances in Precision Health and Emerging Diagnostics for Women. *J. Clin. Med. Res.* **8,** (2019).

38.   Moghimikandelousi, S. et al. Advances in biomonitoring technologies for women's health. *Nature Communications* **16,** 8507 (2025).

39.   Rosen Vollmar, A. K., Mahalingaiah, S. & Jukic, A. M. The menstrual cycle as a vital sign: a comprehensive review. *F S Rev.* **6,** 100081 (2025).

40.   Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. *Obstet. Gynecol.* **120,** 197–206 (2012).

41.   Fraser, I. S., Critchley, H. O. D., Broder, M. & Munro, M. G. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. *Semin. Reprod. Med.* **29,** 383–390 (2011)

42.   Nguyen, B. T. et al. Detecting variations in ovulation and menstruation during the COVID-19 pandemic, using real-world mobile app data. *PLoS One* **16,** e0258314; 10.1371/journal.pone.0258314 (2021).

43.   Soumpasis, I., Grace, B. & Johnson, S. Real-life insights on menstrual cycles and ovulation using big data. *Hum. Reprod. Open* **2020,** hoaa011 (2020).

44.   Grieger, J. A. & Norman, R. J. Menstrual cycle length and patterns in a global cohort of women using a mobile phone app: retrospective cohort study. *J. Med. Internet Res.* **22,** e17109; 10.2196/17109 (2020).

45.   Bull, J. R. et al. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit. Med.* **2,** 83; 10.1038/s41746-019-0152-7 (2019).

46.   Symul, L., Wac, K., Hillard, P. & Salathé, M. Assessment of menstrual health status and evolution through mobile apps for fertility awareness. *NPJ Digit. Med.* **2,** 64; 10.1038/s41746-019-0139-4 (2019).

47.   Sohda, S., Suzuki, K. & Igari, I. Relationship between the menstrual cycle and timing of ovulation revealed by new protocols: analysis of data from a self-tracking health app. *J. Med. Internet Res.* **19,** e391; 10.2196/jmir.7468 (2017).

48.   Markovic, A. et al. Physiological response to the COVID-19 vaccine: insights
from a prospective, randomized, single-blinded, crossover trial. *J. Med. Internet Res.* **26,**
e51120; 10.2196/51120 (2024).

49.   Faust, L. et al. Findings from a mobile application-based cohort are consistent
with established knowledge of the menstrual cycle, fertile window, and conception. *Fertil.*
Steril. **112,** 450–457.e3 (2019).

50.   Thigpen, N., Patel, S. & Zhang, X. Oura Ring as a tool for ovulation detection:
validation analysis. *J. Med. Internet Res.* **27,** e60667; 10.2196/60667 (2025).

51.   Li, K. et al. Characterizing physiological and symptomatic variation in menstrual
cycles using self-tracked mobile-health data. *NPJ Digit. Med.* **3,** 79; 10.1038/s41746-020-
0269-8 (2020).

52.   Jasinski, S. R., Presby, D. M., Grosicki, G. J., Capodilupo, E. R. & Lee, V. H. A
novel method for quantifying fluctuations in wearable derived daily cardiovascular
parameters across the menstrual cycle. *NPJ Digit. Med.* **7,** 373; 10.1038/s41746-024-
01394-0 (2024).

53.   Cunningham, A. C. et al. Chronicling menstrual cycle patterns across the
reproductive lifespan with real-world data. *Sci. Rep.* **14,** 10172; 10.1038/s41598-024-
60373-3 (2024).

54.   Roffler, A., Fleddermann, M.-T., de Haan, H., Krüger, K. & Zentgraf, K. Menstrual
cycle tracking in professional volleyball athletes. *Front. Sports Act. Living* **6,** 1408711;
10.3389/fspor.2024.1408711 (2024).

55.   Bradley, D. et al. Time to conception and the menstrual cycle: an observational
study of fertility app users who conceived. *Hum. Fertil. (Camb)* **24,** 267–275 (2021).

56.   Ramaiyer, M. et al. The association of COVID-19 vaccination and menstrual
health: A period-tracking app-based cohort study. *Vaccine X* **19,** 100501 (2024).

57.   Alvergne, A., Vlajic Wheeler, M. & Högqvist Tabor, V. Do sexually transmitted
infections exacerbate negative premenstrual symptoms? Insights from digital health. *Evol.*
Med. Public Health **2018,** 138–150 (2018).

58.   Vieira, C. S. et al. Real-world validation of a bleeding prediction algorithm in
levonorgestrel intrauterine device users using the MyIUS mobile app. *Contraception* **152,**
111201 (2025).

59.   Frenz, A.-K., Ahlers, C., Beckert, V., Gerlinger, C. & Friede, T. Predicting
menstrual bleeding patterns with levonorgestrel-releasing intrauterine systems. *Eur. J.*
Contracept. Reprod. Health Care **26,** 48–57 (2021).

60.   Beckert, V. et al. Bleeding patterns with the 19.5 mg LNG-IUS, with special focus
on the first year of use: implications for counselling. *Eur. J. Contracept. Reprod. Health*
Care **24,** 251–259 (2019).

61.   The Practice Committee of the American Society for Reproductive Medicine. The
clinical relevance of luteal phase deficiency: a committee opinion. *Fertil. Steril.* **98,** 112–
1117.

62.   Crawford, N. M., Pritchard, D. A., Herring, A. H. & Steiner, A. Z. Prospective
evaluation of luteal phase length and natural fertility. *Fertil. Steril.* **107,** 749–755 (2017).

63.   De Souza, M. J. et al. High prevalence of subtle and severe menstrual
disturbances in exercising women: confirmation using daily hormone measures. *Hum.*

997  *Reprod.* **25,** 491–503 (2010).

998  64.  Beckmann, C. R. B. et al. Preconception and Antepartum Care in *Obstetrics and*
999  *Gynecology,* 7th ed. (eds. Beckman, C. R. B., Herbert, W., Laube, D., Ling, F. & Smith, R)
1000  61–78 (Lippincott Williams & Wilkins, Philadelphia, PA, 2013).

1001  65.  Lenton, E. A., Landgren, B. M., Sexton, L. & Harper, R. Normal variation in the
1002  length of the follicular phase of the menstrual cycle: effect of chronological age. *Br. J.*
1003  *Obstet. Gynaecol.* **91,** 681–684 (1984).

1004  66.  Wegrzynowicz, A. K. et al. Complete cycle mapping using a quantitative at-home
1005  hormone monitoring system in prediction of fertile days, confirmation of ovulation, and
1006  screening for ovulation issues preventing conception. *Medicina (Kaunas)* **58,** (2022).

1007  67.  Baird, D. D. et al. Application of a method for estimating day of ovulation using
1008  urinary estrogen and progesterone metabolites. *Epidemiology* **6,** 547–550 (1995).

1009  68.  Chiazze, L., Jr, Brayer, F. T., Macisco, J. J., Jr, Parker, M. P. & Duffy, B. J. The
1010  length and variability of the human menstrual cycle. *JAMA* **203,** 377–380 (1968).

1011  69.  Li, H. et al. Menstrual cycle length variation by demographic characteristics from
1012  the Apple Women's Health Study. *NPJ Digit. Med.* **6,** 100; 10.1038/s41746-023-00848-1
1013  (2023).

1014  70.  Harley, K. G., Watson, A., Robertson, S., Vitzthum, V. J. & Shea, A. Menstrual
1015  cycle characteristics of U.S. adolescents according to gynecologic age and age at
1016  menarche. *J. Pediatr. Adolesc. Gynecol.* **37,** 419–425 (2024).

1017  71.  Roberts, R. E., Farahani, L., Webber, L. & Jayasena, C. Current understanding
1018  of hypothalamic amenorrhoea. *Ther. Adv. Endocrinol. Metab.* **11,** 2042018820945854
1019  (2020).

1020  72.  Hartz, A. J., Barboriak, P. N., Wong, A., Katayama, K. P. & Rimm, A. A. The
1021  association of obesity with infertility and related menstrual abnormalities in women. *Int. J.*
1022  *Obes.* **3,** 57–73 (1979).

1023  73.  Yeung, E. H. et al. Adiposity and sex hormones across the menstrual cycle: the
1024  BioCycle Study. *Int. J. Obes. (Lond)* **37,** 237–243 (2013).

1025  74.  Itoi, S. et al. Body mass index and menstrual irregularity in a prospective cohort
1026  study of smartphone application users. *NPJ Womens Health* **3**; 10.1038/s44294-025-
1027  00065-z (2025).

1028  75.  Zhang, C. Y. et al. Abnormal uterine bleeding patterns determined through
1029  menstrual tracking among participants in the Apple Women's Health Study. *Am. J. Obstet.*
1030  *Gynecol.* **228,** 213.e1–213.e22 (2023).

1031  76.  Hurst, B. S., Davies, K., Milnes, R. C., Knowles, T. G. & Pirrie. A novel technique
1032  for confirmation of the day of ovulation and prediction of ovulation in subsequent cycles
1033  using a skin-worn sensor in a population with ovulatory dysfunction: a side-by-side
1034  comparison with existing basal body temperature algorithm and vaginal core body
1035  temperature algorithm. *Front. Bioeng. Biotechnol.* **10,** 807139; 10.3389/fbioe.2022.807139
1036  (2022).

1037  77.  Marshall, J. A field trial of the basal-body-temperature method of regulating
1038  births. *Lancet* **2,** 8–10 (1968).

1039  78.  Martinez, A. R. et al. The reliability, acceptability and applications of basal body
1040  temperature (BBT) records in the diagnosis and treatment of infertility. *Eur. J. Obstet.*

Gynecol. Reprod. Biol. **47,** 121–127 (1992).

79. Maijala, A., Kinnunen, H., Koskimäki, H., Jämsä, T. & Kangas, M. Nocturnal finger skin temperature in menstrual cycle tracking: ambulatory pilot study using a wearable Oura ring. *BMC Womens Health* **19,** 150; 10.1186/s12905-019-0844-9 (2019).

80. Shilaih, M. et al. Modern fertility awareness methods: wrist wearables capture the changes in temperature associated with the menstrual cycle. *Biosci. Rep.* **38**; 10.1042/BSR20171279 (2018).

81. Zhu, T. Y. et al. The accuracy of wrist skin temperature in detecting ovulation compared to basal body temperature: prospective comparative diagnostic accuracy study. *J. Med. Internet Res.* **23,** e20710; 10.2196/20710 (2021).

82. Murayama, Y., Tang, Z., Saito, K., Nakano, T. & Mitsui, M. Monitoring basal body temperature rhythm: Abdominal skin temperature measurements taken during sleep as simpler alternative. *IEEE Access* **12,** 182374–182385; 10.1109/ACCESS.2024.3511341 (2024).

83. Lin, G. et al. Understanding wrist skin temperature changes to hormone variations across the menstrual cycle. *NPJ Womens Health* **2,** 35; 10.1038/s44294-024-00037-9 (2024).

84. Alzueta, E. et al. Tracking sleep, temperature, heart rate, and daily symptoms across the menstrual cycle with the Oura Ring in healthy women. *Int. J. Womens Health* **14**, 491–503; 10.2147/IJWH.S341917 (2022).

85. Goodale, B. M. et al. Wearable sensors reveal menses-driven changes in physiology and enable prediction of the fertile window: observational study. *J. Med. Internet Res.* **21**, e13404; 10.2196/13404 (2019).

86. Su, H.-W., Yi, Y.-C., Wei, T.-Y., Chang, T.-C. & Cheng, C.-M. Detection of ovulation, a review of currently available methods. *Bioeng. Transl. Med.* **2,** 238–246 (2017).

87. McKinley, P. S. et al. The impact of menstrual cycle phase on cardiac autonomic regulation. *Psychophysiology* **46,** 904–911 (2009).

88. Baker, F. C. & Lee, K. A. Menstrual cycle effects on sleep. *Sleep Med. Clin.* **13,** 283–294 (2018).

89. Sato, N., Miyake, S., Akatsu, J. & Kumashiro, M. Power spectral analysis of heart rate variability in healthy young women during the normal menstrual cycle. *Psychosom. Med.* **57,** 331–335 (1995).

90. Leicht, A. S., Hirning, D. A. & Allen, G. D. Heart rate variability and endogenous sex hormones during the menstrual cycle in young women. *Exp. Physiol.* **88,** 441–446 (2003).

91. Yu, J.-L. et al. Tracking of menstrual cycles and prediction of the fertile window via measurements of basal body temperature and heart rate as well as machine-learning algorithms. *Reprod. Biol. Endocrinol.* **20,** 118 (2022).

92. Shilaih, M., Clerck, V. de, Falco, L., Kübler, F. & Leeners, B. Pulse rate measurement during sleep using wearable sensors, and its correlation with the menstrual cycle phases, a prospective observational study. *Sci. Rep.* **7,** 1294; 10.1038/s41598-017-01433-9 (2017).

93. Lang, A.-L. et al. Feasibility study on menstrual cycles with Fitbit device (FEMFIT): prospective observational cohort study. *JMIR Mhealth Uhealth* **12**, e50135;

10.2196/50135 (2024).

94.   Altini, M. & Plews, D. What is behind changes in resting heart rate and heart rate
variability? A large-scale analysis of longitudinal measurements acquired in free-living.
Sensors (Basel) **21**; 10.3390/s21237932 (2021).

95.   Sims, S. T., Ware, L. & Capodilupo, E. R. Patterns of endogenous and
exogenous ovarian hormone modulation on recovery metrics across the menstrual cycle.
BMJ Open Sport Exerc. Med. **7,** e001047; 10.1136/bmjsem-2021-001047 (2021).

96.   Pierson, E., Althoff, T., Thomas, D., Hillard, P. & Leskovec, J. Daily, weekly,
seasonal and menstrual cycles in women's mood, behaviour and vital signs. *Nat. Hum.*
Behav. **5,** 716–725; 10.1038/s41562-020-01046-9 (2021).

97.   Godbole, G., Joshi, A. R. & Vaidya, S. M. Effect of female sex hormones on
cardiorespiratory parameters. *J. Family Med. Prim. Care* **5,** 822–824 (2016).

98.   Schmalenberger, K. M. et al. A systematic review and meta-analysis of within-
person changes in cardiac vagal activity across the menstrual cycle: implications for female
health and future studies. *J. Clin. Med.* **8**; 10.3390/jcm8111946 (2019).

99.   Ramesh, A., Nayak, T., Beestrum, M., Quer, G. & Pandit, J. A. Heart rate
variability in psychiatric disorders: a systematic review. *Neuropsychiatr. Dis. Treat.* **19,**
2217–2239 (2023).

100.   Baker, F. C., Mitchell, D. & Driver, H. S. Oral contraceptives alter sleep and raise
body temperature in young women. *Pflügers Arch.* **442,** 729–737 (2001).

101.   Martin, J. G. & Buono, M. J. Oral contraceptives elevate core temperature and
heart rate during exercise in the heat. *Clin. Physiol.* **17**, 401–408 (1997).

102.   de Zambotti, M., Nicholas, C. L., Colrain, I. M., Trinder, J. A. & Baker, F. C.
Autonomic regulation across phases of the menstrual cycle and sleep stages in women
with premenstrual syndrome and healthy controls. *Psychoneuroendocrinology* **38,** 2618–
2627 (2013).

103.   Pan, Q. et al. Wearable-measured heart rate variability and premenstrual
disorder symptoms across menstrual cycle. *medRxiv* doi:10.1101/2024.10.27.24316196
(2024).

104.   Delray, K., Lewis, G. & Hayes, J. F. Tracking mood symptoms across the
menstrual cycle in women with depression using ecological momentary assessment and
heart rate variability. *BMJ Ment. Health* **28**; 10.1136/bmjment-2025-301674 (2025).

105.   Van Reen, E. & Kiesner, J. Individual differences in self-reported difficulty
sleeping across the menstrual cycle. *Arch. Womens Ment. Health* **19,** 599–608 (2016).

106.   Baker, F. C. & Driver, H. S. Self-reported sleep across the menstrual cycle in
young, healthy women. *J. Psychosom. Res.* **56,** 239–243 (2004).

107.   Baker, F. C. & Driver, H. S. Circadian rhythms, sleep, and the menstrual cycle.
Sleep Med. **8**, 613–622 (2007).

108.   Zheng, H. et al. Actigraphy-defined measures of sleep and movement across the
menstrual cycle in midlife menstruating women: Study of women's health across the nation
sleep study. *Menopause* **22,** 66–74 (2015).

109.   Li, D. X., Romans, S., De Souza, M. J., Murray, B. & Einstein, G. Actigraphic and
self-reported sleep quality in women: associations with ovarian hormones and mood. *Sleep*
Med. **16,** 1217–1224 (2015).

110. Costeira, R. et al. Estrogen and COVID-19 symptoms: associations in women
from the COVID Symptom Study. *PLoS One* **16,** e0257051; 10.1371/journal.pone.0257051
(2021).
111. Germini, F. et al. Accuracy and acceptability of wrist-wearable activity-tracking
devices: systematic review of the literature. *J. Med. Internet Res.* **24,** e30791;
10.2196/30791 (2022).
112. Shin, G. et al. Wearable activity trackers, accuracy, adoption, acceptance and
health impact: A systematic literature review. *J. Biomed. Inform.* **93,** 103153;
10.1016/j.jbi.2019.103153 (2019).
113. Fuller, D. et al. Reliability and validity of commercially available wearable devices
for measuring steps, energy expenditure, and heart rate: systematic review. *JMIR Mhealth*
Uhealth **8,** e18694; 10.2196/18694 (2020).
114. Molnar, G. W. Body temperatures during menopausal hot flashes. *J. Appl.*
Physiol. **38,** 499–503 (1975).
115. Freedman, R. R. & Woodward, S. Core body temperature during menopausal hot
flushes. *Fertil. Steril.* **65**, 1141–1144 (1996).
116. Kryder, C. How accurate is Oura's temperature data? *Ōura Health Oy*
https://ouraring.com/blog/temperature-validated-accurate/ (2020).
117. Hasselberg, M. J., McMahon, J. & Parker, K. The validity, reliability, and utility of
the iButton® for measurement of body temperature circadian rhythms in sleep/wake
research. *Sleep Med.* **14,** 5–11 (2013).
118. Burgess, G. E., 3rd, Cooper, J. R., Marino, R. J. & Peuler, M. J. Continuous
monitoring of skin temperature using a liquid-crystal thermometer during anesthesia. *South*
Med. J. **71,** 516–518 (1978).
119. Kräuchi, K. & Wirz-Justice, A. Circadian rhythm of heat production, heart rate,
and skin and core temperature under unmasking conditions in men. *Am. J. Physiol.* **267,**
R819–29 (1994).
120. Driver, H. S., Werth, E., Dijk, D.-J. & Borbély, A. A. The menstrual cycle effects
on sleep. *Sleep Med. Clin.* **3,** 1–11 (2008).
121. Miller, D. J., Sargent, C. & Roach, G. D. A validation of six wearable devices for
estimating sleep, heart rate and heart rate variability in healthy adults. *Sensors (Basel)* **22**;
10.3390/s22166317 (2022).
122. Kinnunen, H., Rantanen, A., Kenttä, T. & Koskimäki, H. Feasible assessment of
recovery and cardiovascular health: accuracy of nocturnal HR and HRV assessed via ring
PPG in comparison to medical grade ECG. *Physiol. Meas.* **41,** 04NT01 (2020).
123. Kinnunen, H. O. & Koskimäki, H. The HRV of the ring - comparison of nocturnal
HR and HRV between a commercially available wearable ring and ECG. *Sleep* **41,** A120–
A120 (2018).
124. Boonya-Ananta, T. et al. Synthetic photoplethysmography (PPG) of the radial
artery through parallelized Monte Carlo and its correlation to body mass index (BMI). *Sci.*
Rep. **11,** 2570; 10.1038/s41598-021-82124-4 (2021).
125. Osorio-Sanchez, L., May, J. M. & Kyriacou, P. Evaluation of skin pigmentation
effect on photoplethysmography signals using a vascular finger phantom with tunable
optical and mechanical properties. *J. Biomed. Opt.* **30,** 117002 (2025).

126.   Icenhower, A. et al. Investigating the accuracy of Garmin PPG sensors on differing skin types based on the Fitzpatrick scale: cross-sectional comparison study. *Front. Digit. Health* **7**; 10.3389/fdgth.2025.1553565 (2025).

127.   Zhu, K. et al. Vision-based heart and respiratory rate monitoring during sleep - a validation study for the population at risk of sleep apnea. *IEEE J. Transl. Eng. Health Med.* **7**, 1900708; 10.1109/JTEHM.2019.2946147 (2019).

128.   Hayashi, K., Kawashima, T. & Suzuki, Y. Effect of menstrual cycle phase on the ventilatory response to rising body temperature during exercise. *J. Appl. Physiol. (1985)* **113,** 237–245 (2012).

129.   Berryhill, S. et al. Effect of wearables on sleep in healthy individuals: a randomized crossover trial and validation study. *J. Clin. Sleep Med.* **16,** 775–783; 10.5664/jcsm.8356 (2020).

130.   Brar, T. K., Singh, K. D. & Kumar, A. Effect of different phases of menstrual cycle on heart rate variability (HRV). *J. Clin. Diagn. Res.* **9,** CC01–4 (2015).

131.   Voronova, N. V., Meigal, A. Y., Yelaeva, L. E. & Kuzmina, G. I. Heart rate variability in women during various seasons and phases of the menstrual cycle. *Èkol. čeloveka* **22,** 20–26 (2015).

132.   Asgari Mehrabadi, M. et al. Sleep tracking of a commercially available smart ring and smartwatch against medical-grade actigraphy in everyday settings: instrument validation study. *JMIR Mhealth Uhealth* **8,** e20465; 10.2196/20465 (2020).

133.   Kubala, A. G. et al. Field-based measurement of sleep: agreement between six commercial activity monitors and a validated accelerometer. *Behav. Sleep Med.* **18,** 637–652 (2020).

134.   Nulty, A. K., Chen, E. & Thompson, A. L. The Ava bracelet for collection of fertility and pregnancy data in free-living conditions: An exploratory validity and acceptability study. *Digit. Health* **8**; 10.1177/20552076221084461 (2022).

135.   Department for Health and Social Care (DHSC). Results of the 'Women's Health – Let's talk about it' survey. *UK Government* https://www.gov.uk/government/calls-for-evidence/womens-health-strategy-call-for-evidence/outcome/results-of-the-womens-health-lets-talk-about-it-survey (2022).

136.   Kerman, S. Mirror/mirror: women's reflections on beauty, age and media — authenticity and menopause *AARP* https://www.aarp.org/pri/topics/aging-experience/older-women-authentic-representation-menopause/ (2025).

137.   Hudson, N. The missed disease? Endometriosis as an example of 'undone science'. *Reprod. Biomed. Soc. Online* **14,** 20–27; 10.1016/j.rbms.2021.07.003 (2022).

138.   Meuleman, C. et al. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. *Fertil. Steril.* **92,** 68–74 (2009).

139.   Nassaralla, C. L. et al. Characteristics of the menstrual cycle after discontinuation of oral contraceptives. *J. Womens Health (Larchmt)* **20,** 169–177 (2011).

140.   Blaser, B. L., Weymar, M. & Wendt, J. Alleviating premenstrual symptoms with smartphone-based heart rate variability biofeedback training: a pilot study. *Front. Digit. Health* **6**; 10.3389/fdgth.2024.1337667 (2024).

141.   Pasadyn, S. R. et al. Accuracy of commercially available heart rate monitors in athletes: a prospective study. *Cardiovasc. Diagn. Ther.* **9,** 379–385 (2019).

142.   Schweizer, T. & Gilgen-Ammann, R. Wrist-worn and arm-worn wearables for
monitoring heart rate during sedentary and light-to-vigorous physical activities: device
validation study. *JMIR Cardio.* **9,** e67110; 10.2196/67110 (2025).
143.   Vidal, C. The ethics of menstrual tracking applications. *Nat. Hum. Behav.* **8,** 2076
(2024).
144.   Alfawzan, N., Christen, M., Spitale, G. & Biller-Andorno, N. Privacy, data sharing,
and data security policies of women's mHealth apps: scoping review and content analysis.
JMIR Mhealth Uhealth **10,** e33735; 10.2196/33735 (2022).
145.   Dong, Z., Wang, L., Xie, H., Xu, G. & Wang, H. Privacy analysis of period
tracking mobile apps in the post-roe v. Wade era. in *Proceedings of the 37th IEEE/ACM*
International Conference on Automated Software Engineering (ASE '22) 1-6
https://doi.org/10.1145/3551349.3561343 (Association for Computing Machinery, 2022).
146.   Haddaway, N. R., Page, M. J., Pritchard, C. C. & McGuinness, L. A. An R
package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with
interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst. Rev.*
18, e1230; 10.1002/cl2.1230 (2022).
147.   Namie, T. et al. Menstrual variations of sleep-wake rhythms in healthy women.
Sleep Biol. Rhythms **23,** 5–12 (2025).
148.   Meserve, C. New WHOOP 4.0 Metric: Skin Temperature. *WHOOP, Inc*
https://www.whoop.com/de/en/thelocker/how-whoop-tracks-skin-temperature/ (2021).
149.   Gobinath, A. What sensors are on the Ava bracelet? *Ava*
https://www.avawomen.com/avaworld/sensors-ava-bracelet/ (2018).
150.   Track your nightly wrist temperature changes with Apple Watch. *Apple Inc*
https://support.apple.com/en-us/102674 (2025).
151.   What is the skin temperature feature in Garmin Connect? *Garmin Ltd*
https://support.garmin.com/en-US/?faq=RDXq6E5Iaq9rD1l1kTObf6.
152.   How can Fitbit help me track my temperature? *Google LLC*
https://support.google.com/fitbit/answer/14237207?sjid=13360756588868122580-NC.
153.   Resting Heart Rate. *Ōura Health Oy* https://support.ouraring.com/hc/en-
us/articles/360025588793-Resting-Heart-Rate.
154.   Jasinski, S. R., Rowan, S., Presby, D. M., Claydon, E. A. & Capodilupo, E. R.
Wearable-derived maternal heart rate variability as a novel digital biomarker of preterm
birth. *PLoS One* **19**, e0295899; 10.1371/journal.pone.0295899 (2024).
155.   Haghayegh, S., Khoshnevis, S., Smolensky, M. H. & Diller, K. R. Accuracy of
PurePulse photoplethysmography technology of Fitbit Charge 2 for assessment of heart
rate during sleep. *Chronobiol. Int.* **36,** 927–933 (2019).
156.   Ding, J., Hong, W. & and Li, H. Comparison of the accuracy of three wrist-worn
tracking devices when measuring heart rate during aerobic exercise. in *International*
Society of Biomechanics in Sports Conference (ISBS '22)
https://commons.nmu.edu/isbs/vol40/iss1/35 (International Society of Biomechanics in
Sports, 2022).
157.   Heart rate measurements on my HUAWEI wearable device are inaccurate.
HUAWEI https://consumer.huawei.com/en/support/content/en-us00733859/.
158.   How accurate is Oura's respiratory rate? *Ōura Health Oy*

https://ouraring.com/blog/how-accurate-is-ouras-respiratory-
rate/?srsltid=AfmBOor3r1JoVjMnBWWGjnoWZGjxjG26xlGPK118jIb0PE2ly8yinlx0 (2020).
159. Capodilupo, E. Understanding respiratory rate: What it is, what's normal & why
you should track it. *WHOOP, Inc* https://www.whoop.com/qa/en/thelocker/what-is-
respiratory-rate-normal/ (2021).
160. Renevey, P. et al. Respiratory and cardiac monitoring at night using a wrist
wearable optical system. *arXiv* https://doi.org/10.1109/EMBC.2018.8512881 (2017).
161. How do I track breathing rate in the Fitbit app? *Google LLC*
https://support.google.com/fitbit/answer/14237113?sjid=13360756588868122580-NC.
162. Natarajan, A. et al. Measurement of respiratory rate using wearable devices and
applications to COVID-19 detection. *NPJ Digit. Med.* **4,** 136; 10.1038/s41746-021-00493-6
(2021).
163. Cao, R. et al. Accuracy assessment of Oura Ring nocturnal heart rate and heart
rate variability in comparison with electrocardiography in time and frequency domains:
comprehensive analysis. *J. Med. Internet Res.* **24,** e27487; 10.2196/27487 (2022).
164. Meisel, L. What your Ava data means. *Ava AG*
https://www.avawomen.com/avaworld/ava-data-means (2017).
165. Grandner, M. A. et al. Performance of a multisensor smart ring to evaluate sleep:
in-lab and home-based evaluation of generalized and personalized algorithms. *Sleep* **46,**
(2023).
166. What should I know about Fitbit sleep stages? *Google LLC*
https://support.google.com/fitbit/answer/14236712#zippy=%2Chow-does-my-fitbit-device-
automatically-detect-my-sleep-stages.
167. Haghayegh, S., Khoshnevis, S., Smolensky, M. H., Diller, K. R. & Castriotta, R. J.
Accuracy of wristband Fitbit models in assessing sleep: systematic review and meta-
analysis. *J. Med. Internet Res.* **21,** e16273; 10.2196/16273 (2019).
168. HUAWEI Band 8 Principles behind sleep tracking. *Huawei*
https://consumer.huawei.com/en/support/content/en-us15963854/.
169. Mei, L., He, Z. & Hu, L. Accuracy of the Huawei GT2 smartwatch for measuring
physical activity and sleep among adults during daily life: instrument validation study. *JMIR*
Form. Res. **8,** e59521; 10.2196/59521 (2024).
1292
1293
1294

1296 # 8. Figures

1297

Figure 1: Reported changes in biometrics across the menstrual cycle, as recorded with wearables. Biometrics that
have been characterised include a) skin temperature, b) resting heart rate, c) respiratory rate, and d) heart rate
variability (HRV). Where phases were estimated based on time from menses or ovulation, we assumed a 28-day
cycle with ovulation on day 14. Data from longer cycles (35 days; studies noted with *) were normalised to a 28-day
cycle. Resting heart rate is in units of beats per minute. HRV is shown as the root mean square of successive
differences (RMSSD) in milliseconds, either directly reported or calculated from reported percentage change in
fluctuation from a mean. Respiratory rate is breaths per minute at rest. Skin temperature is in degrees Celsius
measured at rest.
1306

1307
1308
1309
1310 **Figure 2:** PRISMA flow diagram in the search of papers associated with the menstrual cycle. Adapted
1311 from the PRISMA flow diagram[146].

1331
1332
1333
1334

9. Tables

Table 1: Menstrual cycle characteristics recorded with digital health tools. In this table, we summarise the results of all studies that reported at minimum cycle length and age.

Ref	Digital health tool	Cohort size	Age (yrs; mean ± SD, [range])	Ovulation estimation method	Was naturally cycling status confirmed?	Additional inclusion criteria	Cycle or phase length (days; mean ± SD, unless noted)			Bleed length (days; mean ± SD, unless noted)	Inter-cycle variability (days; mean ± SD, unless noted)
							Cycle	Follicular	Luteal		
42	Natural Cycles app	18,076	33±6.8	Algorithm with BBT on at least 10+ days in 1 cycle	Yes	No medical condition that may influence cycle regularity	29.4			4.2; range [4.2-4.2]	
43	Clearblue connected ovulation test system	32,595	age not reported, but app intended for 18+	LH urine test	Yes	Cycle length not 50% shorter or longer than baseline cycle length	28 mode	15 mode			For women with a 28-day cycle: 62%: ±2; 26%: ≥4; 19%: ≥5
44	Flo app	1.5M	40% were 18-24, [18-55]	LH urine test	No, contraceptive pill use included	3 cycles of data available	28 mode	13 mode	15 mode		25%: 0 to 1.5; 69%: less than 6
45	Natural Cycles app	124,648	30, [18-44]	Algorithm using BBT on >50% + LH if available	Yes	Cycle length 10-90 days	29.3±5	16.9±5.3	12.4±2.4	4.0±1.5	2.6±2.5
46	Kindara app	13,674	29±6	Algorithm using BBT and FAM	Yes	No midcycle bleed that is 4 or more days longer than bleed	28	16 median	12 median		
	Sympto app	199,293	30±6	Algorithm using BBT and FAM	Yes	No midcycle bleed, ovulation detected	28	16 median	13 median		
47	Luna Luna app	7,043	33, [20-45]	31% clinical diagnosis, 54% test kit	Yes	Cycle length 21-45 days	29.8	14.8; range [10-23]	13.91; range [10-19]		

48	Ava bracelet	179	41±8, [19-55]	Algorithm using 5 biometrics including skin temperature, heart rate	No, any contraceptive users included	Vaccinated with > 1 cycle	28	16.92	11.02	4.8	
49	Ovia app	98,903	[18-45], 70% 25-34	LH urine test	Yes, newly attempting conception	Cycle length ≥19 and <60 days	29.6±5.4				
50	Oura Ring	1007	18+, 51% 27-34	LH urine test	Yes, no hormone use or pregnancy	Cycle length>=12 days and <=90 days	<1% ≤ 21 15%: 22-26 57%: 27-31 19%: 32-35 8%: ≥36				67%: 0-3 21%:4-7 12%:>7
51	Clue app	378,694	25, [21-33]	None	Yes	None	29.7±6			4.1±1.8	4.15±4.94
52	WHOOP 3.0/4.0	11,629	35±7	None	No, contraceptive pill use included	Cycle length 21-35 days, bleed duration ≤7 days	27.4±2			4.7±1.1	
		9,968	35±7	None	Yes		27.4±2			4.7±1.0	
		1,161	31±7	None	No, only contraceptive pill users		27.7±1			4.4±1.1	
53	Flo app	19.2M	[18-55], 53% 18.5-24.9	None	No, but excludes contraception reminder users	Cycle length ≥10 days	28.5±3.2			5.2±0.9	4.01±4.74
54	FitrWomen app	20 athletes	25±2, [19-28]	None	No, 4 contraceptive users included	At least 1 cycle available	34.9±11.6				
55	Ovia app	45,360	31±5, [18-45]	None	Yes	Women who conceived within 1 year of tracking	29.8			4.4±4.7	86%: <9 14%: 9-25

Ref	Tool	n	Age	Measurement	Contraceptive	Subgroup	Cycle length			Bleed	
56	Clue app	6,897	[18+], 29% 18-24	None	Yes	Cycle length ≤90 days, vaccinated group	29.9±7.1, 2nd cycle post vaccination			If vaccinated during menses: 4.5±1.8; else: 4.2±1.8	
		662				Cycle length ≤90, unvaccinated group	29.6±7.1			4.3±1.6	
57	Clue app	584	median 26	None	Yes	Cycle length 24-38 days and bleed duration <9 days	29			4 median	
		223	median 24	None	No, contraceptive users		28			5 median	
		40 with STI	median 27	None	Yes		30			4 median	
		18 with STI	median 26	None	No, contraceptive users		28			4 median	
76	Proprietary sensor + vaginal sensor	80	32, [22-46]	Vaginal temperature recordings	Yes, attempting conception	PCOS diagnosis	40.9±30.1				
						Hypothyroid diagnosis	31.2±4				
						PCOS + Hypothyroid diagnosis	76.2±104.8				
						No known diagnosis	35.4±16.6				

1338
1339 FAM - fertility awareness methods; LH - luteinizing hormone; BBT - basal body temperature; PCOS - Polycystic ovary syndrome; STI - sexually transmitted
1340 infection

1341 **Table 2:** Insights from monitoring of menstrual cycles with digital health tools. Naturally cycling women, unless otherwise stated.

Finding	Ref.	Measurement Tool	Phase determination	Cohort (n participants; mean age ± SD; n cycles, when available)	Notable additional details
2.2.1 Characterising and refining normative trends in menstrual cycle length, menstrual bleed length, and timing of ovulation					
Bleed phase duration changed with very	45	Natural Cycles app	Ovulation estimated algorithmically from self-	n = 124,648; age = 30.3 yrs;	Very short cycles had shorter menstrual bleed lengths by 12%. Very long cycles had longer

short and long cycles			reported BBT and LH urine test when available	cycles = 612,613 ovulatory	menstrual bleed lengths by 6%
Long ovulatory cycles had proportionally longer follicular phases	45	Natural Cycles app	Ovulation estimated algorithmically from self-reported BBT and LH urine test when available	n = 124,648; age = 30.3 yrs; cycles = 612,613 ovulatory	Very short 15-20 day cycles had 34% shorter follicular and 35% shorter luteal phases. Long 36-50 day ovulatory cycles had 66% longer follicular phases and only 5% longer luteal phases.
	43	Clearblue connected ovulation test system	Ovulation estimated with LH urine test	n = 32,595; age not reported, but app intended for 18+; cycles = 75,981	App intended to aid conception. Follicular phase correlated with cycle length (Pearson r=0.77, p<0.001). Luteal phase correlated with cycle length, but not as strongly (r=0.37, p<0.001)
2.2.1 Characterising and refining normative trends in menstrual cycle length, menstrual bleed length, and timing of ovulation: Cycle irregularities					
Irregular cycles were associated with more negative symptoms and less change in heart rate	51	Clue app	Ovulation not estimated	n = 378,694; age = 21-33 yrs; cycles = 4.9M	Users with consistently highly variable menstrual cycle length (median cycle length difference ≥ 9 days) more likely associated with headaches and tender breasts
	92	Ava bracelet, PulseOn, Basis Peak	Ovulation estimated with LH urine test	n = 91; age = 33.2±4.7 yrs; cycles = 274 ovulatory	Irregular cycles (outside 24-35 day-range) showed less resting heart rate change between ovulation and the luteal phase (1.8 vs 2.1 bpm) and luteal to menstrual phase
Irregular cycles were most common at 51-55 yrs	53	Flo app	Ovulation not estimated	n = 19,266,573; age = 18-55 yrs; cycles = ≥3 each	Irregularity (≥2 cycle lengths per year differing by >7 days) was highest in age 51–55 (44.7%), and lowest in age 36–40 (28.3%)
In healthy cohorts, 8% showed abnormal cycle length (<24 or > 38 days), 2.5% showed anovulation	42	Natural Cycles app	Ovulation estimated algorithmically from self-reported BBT and LH urine test when available	n = 18,076; age = 33 yrs; cycles = 214,426	8.7-8% show abnormal cycle length and menses >8 days
					Anovulation in 2.9% to 2.5% of cycles

Ovulation was not indicative of ovulatory function	[66]	Proov app	Urine tests for LH, FSH, estrogen & progesterone metabolites	n = 40, age = 34 yrs; cycles = 40	38/40 cycles were ovulatory (exhibited LH and progesterone rise) but only 22/40 had sustained progesterone rise indicative of ovulatory function
Abnormal uterine bleeding observed in 17% of naturally cycling women and was associated with menstrual conditions	[75]	Apple Research app	Ovulation not estimated	n = 18,875; age = 33±8.2 yrs; cycles = 16±9 each	Of the 17%, 2.9% had irregular menses, 8.4% infrequent menses, 2.3% prolonged bleeding, and 6.1% intermenstrual bleeding
					Bleeding was increased in women with PCOS (+19%), hyperthyroidism (+34%), hypothyroidism (+17%), endometriosis (+28%), cervical dysplasia (+20%) and fibroids (+14%)
51% of women reported spotting or absence of bleed after hormonal IUD insertion	[58]	MyIUS app	Ovulation not estimated	n = 1,734; age = 18+ (42% age 18-25) yrs; cycles = not reported	During the 90–270 day post-insertion period, women reported experienced mainly spotting (41%), bleeding (48%), or amenorrhea (11%)
2.2.2 Differences in menstrual cycle characteristics across demographic groups and other subpopulations: Age					
The amplitude of resting heart rate and HRV change decreased with age	[52]	WHOOP 3.0 or 4.0	Ovulation not estimated	n = 9,968 naturally cycling, 3,322 combined pill; age = 18+ yrs; cycles = 45,811	Amplitude change in resting heart rate significantly decreased with age
					Amplitude change in HRV significantly decreased with age
	[96]	Clue app	Ovulation not estimated	n = 499,000; age = 21.2; cycles = not reported, ≥12 months data per person	Premenstrual magnitude of increase in resting HR decreased with age
Premenstrual weight gain was less with age	[96]	Clue app	Ovulation not estimated	n = 499,000; age = 21.2; yrs; cycles = not reported, over ≥12 months data per person	Increase in premenstrual weight gain decreased with age
Premenstrual negative mood rose with age					Premenstrual negative mood effect increased with age from age 15-20 to 30-35
Highly variable, short, and long cycles were greater in year 1 post-menarche	[70]	Clue app	Ovulation not estimated	n = 6,486; age = 16, range [13-18]; cycles = 38,916	51.5% of people showed variable cycles (<21 or >45 days or bleed phase >8 days). Females <1 year vs 6+ years post-menarche had lighter flow but more highly variable or short cycles

Earlier menarche was related to cycle length and bleeding					Menarche age ≤10 vs 14+ was associated with shorter cycle length, increased odds of dysmenorrhea, and less high cycle variability
Cycles shortened with age then became more variable	53	Flo app	Ovulation not estimated	n = 19,266,573; age = 18-55 yrs; cycles = ≥3 each	From age 18-24, cycles shortened from 28.5 days to 27 days and cycle variability decreased until age 46-50, when menstrual cycles and menses became longer and more variable
	69	Apple Research app	Ovulation not estimated	n = 12,608; age = 33.8 yrs; cycles = 165,668	Menstrual cycle length shortened by 2.4 days with up to age 50 then became longer. Cycle variability was lowest age 35-39, and increased 200% for age 50+
	45	Natural Cycles app	Ovulation estimated algorithmically from self-reported BBT and LH urine test when available	n = 124,648; age = 30.3 yrs; cycles = 612,613 ovulatory	From age 18 to 45, cycles shortened from 30 to 27 days and cycle variability decreased by 0.5 days. Only follicular phase shortened
Luteal phase length was stable with age	44	Flo app	Ovulation estimated with LH urine test	n = 1,579,819; age = 18+ (40% aged 18-24) yrs; cycles = ≥1 each	Naturally cycling women targeted by excluding users with oral contraceptive reminders. Luteal phase remained 15 days long across ages
2.2.2 Differences in menstrual cycle characteristics across demographic groups and other subpopulations: BMI					
High BMI was associated with altered menstrual characteristics	45	Natural Cycles app	Ovulation estimated algorithmically from self-reported BBT and LH urine test when available	n = 124,648; age = 30.3 yrs; cycles = 612,613 ovulatory	In ovulatory cycles, those with BMI >35 had 0.4 days greater cycle variability compared with BMI 18.5-25.
	44	Flo app	Ovulation estimated with LH urine test	n = 1,579,819; age = 18+ (40% aged 18-24) yrs; cycles = ≥1 each	Naturally cycling women targeted by excluding users with oral contraceptive reminders. Women with the lowest BMI tended to have the highest cycle length variability. More women with BMI >35 had a long median cycle length of ≥36 days than BMI ≤35.

	69	Apple Research app	Ovulation not estimated	n = 12,608; age = 33±8 yrs; cycles = 165,668	Menstrual cycle length increased with BMI (compared to participants with BMI 18.5-25, participants with BMI 30-34, 35-40, and ≥40 had 0.5, 0.8, and 1.5 days longer, respectively). Those with BMI>25.5 had more cycle variability and more likelihood of a long cycle (>38 days) compared with BMI ≤25.5.
	74	Luna Luna	Ovulation or anovulation estimated with BBT	n=8,745; age = 30.1±7.2 yrs cycles =191,426	Compared to BMI of 20, those with BMI of 16 or 30 had 1 day longer cycles and 1.1 or 1.5 days more cycle length variability, respectively. Compared to BMI 18.5-22.5, those with BMI>35 had higher risk of absent menstrual bleeding (OR 1.94), those with BMI of 22.5-35 and BMI>35 had higher risk of irregular menstrual bleeding (OR of 1.56 and 2.63, respectively).
	75	Apple Health app	Ovulation not estimated	n = 18,875; age = 33±8.2 yrs; cycles = 16±9 each	Prevalence of infrequent menses increased in those with BMI>30,>35, and >40 by 31,25, and 51%, respectively. Those with BMI >40 had an 18% higher prevalence of abnormal bleeding.
Low BMI was associated with altered menstrual characteristics	44	Flo app	Ovulation estimated with LH urine test	n=1,579,819; age = 18+ (40% aged 18-24) yrs; cycles = ≥1 each	Naturally cycling women targeted by excluding users with oral contraceptive reminders. Women with the lowest BMI showed the most cycle length variation
	74	Luna Luna	Ovulation or anovulation estimated with BBT	n=8,745; age = 31.1±7.2 yrs; cycles =191,426	Compared to BMI of 18.5 to 22.9, a higher risk of absent menstrual bleeding was found with BMI <18.5 (OR 1.78). Compared to those with BMI = 20, those with BMI = 16 had a greater (+1.03 day) mean cycle length and +1.1day more cycle variability
	45	Natural Cycles app	Ovulation estimated algorithmically from self-reported BBT and LH urine test when available	n = 124,648; age = 30.3 yrs; cycles = 612,613 ovulatory	0.2 day (5%) longer mean menstrual bleed length in those with BMI 15-18.5 compared to BMI 18.5 to 25)
HRV change was related to BMI	52	WHOOP 3.0 or 4.0	Ovulation not estimated	n = 9,968; age = 35 yrs; cycles = 45,811	Amplitude of HRV change across the menstrual cycle increased with BMI

2.2.2 Differences in menstrual cycle characteristics across demographic groups and other subpopulations: Race and Ethnicity					
Ethnicity was associated with differences in cycle length and infrequent menses prevalence	69	Apple Research app	Ovulation not estimated	n = 12,608; age = 33±8 yrs; cycles = 165,668	Menstrual cycles were 1.6 days longer for Asian and 0.7 days longer for Hispanic participants with more cycle variability compared to White non-Hispanic participants. No difference was seen with Black participants
	75	Apple Research app	Ovulation not estimated	n = 18,875; age = 33±8.2 yrs; cycles = 16±9 cycles each	Black participants had a 33% higher prevalence of infrequent menses compared to White non-Hispanics after controlling for age and BMI
2.2.3 Physiological changes throughout the menstrual cycle					
Skin temperature was lowest in the menstrual or follicular phase then increased to a peak in the late luteal phase	85	Ava bracelet	Ovulation estimated with LH urine test	n = 193; age = 33±4 yrs; cycles = 705 ovulatory	Range of 0.45°C with minimum of 33.87°C in the follicular phase
	84	Oura Ring (v 2.43.1)	Ovulation estimated with LH urine test	n = 26; age = 24±1yrs; cycles = 1 ovulatory each	Range of 0.32°C. Minimum in ovulation (only 0.01°C less than menses) and highest in the luteal phase
	79	Oura Ring	Ovulation estimated with LH urine test	n = 22; age = 35±9 yrs; cycles = 2±1 ovulatory each	Range of 0.30±0.12°C with lower value in follicular compared to the luteal phase
	80	Ava bracelet	Ovulation estimated with LH urine test	n = 136; age = 33.66±3.86 yrs; cycles = 437 ovulatory	Range of 0.81°C with minimum of 35.23°C in the follicular phase (not menses), and peak in early luteal phase
	81	Ava bracelet	Ovulation estimated with LH urine test	n = 57; age = 27±4 yrs; cycles = 193, 170 ovulatory	Range of 0.29±0.21°C where lower in follicular compared to luteal phase
	82	Abdominal sensor	Ovulation estimated with LH urine test	n = 41; age 39±6 yrs; cycles = 100	Detecting the transition to the peak temperature. Change of 0.34°C from 36.3±0.03°C to 36.7±0.03°C, transition ~4 days from LH surge
	83	Fitbit Sense	Ovulation estimated with LH and estrogen urine test	n = 49; age 18-30 yrs; cycles = 123	Change of 0.3°C with minimum of 33.7±0.8°C in late follicular and peak in luteal phase of 34.0±1°C
Resting heart rate increased across the	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4	n = 3,870; age = 34±7 yrs; cycles = 13,535	Mean range of 3 bpm from 55.5 to 58.5bpm with minimum in the early follicular phase

menstrual cycle			equal phases		
	92	Basis Peak, Ava bracelet, PulseOn	Ovulation day estimated with LH urine test	n = 91; age = 33±5yrs; cycles = 274 ovulatory	Mean range of 3.8 bpm with minimum in the menstrual phase
	85	Ava bracelet	Ovulation estimated with LH urine test	n = 193; age = 33±4 yrs; cycles = 705 with LH surge	Mean range of 3.9 bpm with minimum of 56.6 bpm in the follicular phase
	84	Oura Ring (v 2.43.1)	Ovulation estimated with LH urine test	N = 26; age = 24±1 yrs; cycles = 1 ovulatory each	Mean range of 2.7 bpm from 63.3 to 66 bpm with minimum during menses
	52	WHOOP 3.0 or WHOOP 4.0	Ovulation not estimated	n = 9,968; age = 18+; cycles = 45,811	Mean of 60± 8 bpm with amplitude 2.73 bpm ±1.9. Lowest point at day 5 and peak at day 26
	93	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n = 33; age = 24±3 yrs; cycles = 50	Mean range of 4bpm from 64 in menses, mean 67±7 bpm. Study included 4 contraceptive users
	94	HRV4Training app	Ovulation not estimated, cycle bisected into two phases	n = 5,425; age (all gender) = 37±1 yrs; cycles = ≥5 each	Mean 61±8 bpm. 1.6% increase between follicular and luteal phase. Study included an unspecified number of contraceptive users
	91	Huawei Band 5	Ovarian ultrasound and serum testing	n = 89 regular, 25 irregular; median age = 31 yrs; cycles = 77	Range 2.7 bpm, with minimum in the menstrual phase and maximum in the luteal phase
Respiratory rate decreased in the late follicular phase then increased through the luteal phase	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4 equal phases	n = 3,870; age = 34±7 yrs; cycles = 13,535	Range of 0.3 pm with minimum of 15.9 bpm in the late follicular phase
	85	Ava bracelet	Ovulation estimated with LH urine test	n = 193; age = 33±4 yrs; cycles = 705 ovulatory	Range of 0.64 bpm with minimum of 16.4 bpm in fertile window. Higher in late luteal phase compared to menses
HRV decreased across the menstrual cycle	94	HRV4Training app	Ovulation not estimated, cycle bisected into two phases	n = 5,425; age (all gender) = 37±12 yrs; cycles = ≥5 each	Daytime RMSSD decreased 3.2% from follicular to luteal phase. Study included an unspecified number of contraceptive users

	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4 equal phases	n = 3,870; age = 34±7 yrs; cycles = 13,535	Nocturnal RMSSD decreased from 70.1ms in the follicular phase to luteal phase in participants not using hormonal birth control. Range was 6.6 ms
	85	Ava bracelet	Ovulation estimated with LH urine test	n = 193; age = 33±4 yrs; cycles = 705 with LH surge	HRV ratio range of 0.24. Nocturnal HRV ratio trended higher in the follicular and fertile phase compared to the luteal phase but was not significant after Bonferroni correction.
	84	Oura Ring (v 2.43.1)	Ovulation estimated with LH urine test	n = 26; age = 24±1 yrs; cycles = 1 ovulatory each	Nocturnal RMSSD was lower in the late luteal than in menses phase
	52	WHOOP 3.0 or 4.0	Ovulation not estimated	n = 9,968; age = 18+ yrs cycles = 45,811	Nocturnal RMMSD peaked at day 5, decreasing to a minimum at day 27 with range 4.65±6.9 ms
	91	Huawei Band 5	Ovarian ultrasound and serum testing	n = 89 regular, 25 irregular; median age = 31 yrs; cycles = 77	The natural logarithm of SDNN decreased while the low frequency to high frequency ratio increased from the follicular to luteal phase
Sleep did not change across the menstrual cycle	84	Oura Ring (v 2.43.1)	Ovulation estimated with LH urine test	n = 26; age = 24±1 yrs; cycles = 1 ovulatory each	No difference in total sleep time, sleep onset latency, wake after sleep onset, and sleep stages. Sleep efficiency was marginally lower in the mid-luteal phase compared with menses
	93	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n = 33; age = 24±3 years; cycles = 50 ovulatory	No change in sleep duration between phases. Included 4 contraceptive users
	147	Luna-Luna app	Ovulation estimated with LH urine test	n = 10; age = 22±1 yrs; cycles = not reported	No significant differences in sleep duration across phases. Sleep quality was higher in early and late follicular phase compared to menses or the early or late luteal phase
2.2.3 Physiological changes throughout the menstrual cycle: Effects of hormonal contraception on physiology					
Combined pill users showed overall higher heart rate with less change across the cycle; different	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4 equal phases	n = 3,870 naturally cycling, 455 combined pill; age = 34±7 yrs; cycles = 13,535	Resting heart rate range of 1.5 bpm with minimum in early follicular phase, peak of 59 bpm in the late follicular phase, and decrease into the late luteal phase; unlike the increase from follicular to luteal phase in naturally cycling

patterns of HRV and respiratory rate change					women. Resting heart rate was elevated 2 bpm throughout the follicular phase compared with that of naturally cycling women.
	52	WHOOP 3.0 or 4.0	N/A	n = 9,968 naturally cycling, 3322 combined pill; age = 18+; cycles = 45,811	Resting heart rate showed less fluctuation in women on the combined pill compared to those naturally cycling (0.28 vs 2.73 bpm, respectively)
	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4 equal phases	n = 3,870 naturally cycling, 455 combined pill; age = 34±7 yrs; cycles = 13,535	HRV range of 2.5 ms; HRV decreased across the follicular phase then rose during the luteal phase, unlike naturally cycling women whose HRV decreased across cycle.
					Respiratory rate range of 0.2 rpm, with minimum of 16 rpm in early follicular phase and peak in late luteal phase; contrast with range of 0.45 rpm in naturally cycling women whose lower minimum of 15.75 rpm occurred in late follicular phase, though also peaked in late luteal phase.
Progestin-only pill users showed similar resting heart rates and HRV to naturally cycling women, but increased respiratory rate across the menstrual cycle	95	WHOOP ≤3.0	Ovulation not estimated, cycle divided into 4 equal phases	n = 3,870 naturally cycling, 269 progestin-only (pill or IUD not specified); age = 33.5±7.3 yrs; cycles = 13,535	Heart rate range of 2.2 bpm, rising from early follicular to late luteal phase.
					HRV range of 5.5 ms; HRV decreased from 71 ms in the early follicular to 65.5 ms in the early luteal phase, and rose to 66.5 ms in the late luteal phase.
					Respiratory rate range of 0.2 rpm, with minimum of 16 rpm in early follicular phase and peak in late luteal phase; no decrease in the late follicular phase seen in naturally cycling women.
2.2.4 Linking physiology and symptoms across the menstrual cycle					
HRV metrics were inversely associated with premenstrual	103	Huawei Fitness Tracker 6 Pro	N/A	n = 125 without PMDs, 68 with PMDs;	In women with PMDs, nocturnal HRV metrics pre and post menses were inversely associated with symptoms, particularly the affective

			age = 20±2 yrs; cycles = 293	Women with PMDs showed more HRV change in the premenstrual week compared to those with only premenstrual syndrome
disorder (PMD) symptoms and mood and decreased more with more severe diagnosis	104	Juli app (HRV data integrated from other apps or devices)	Ovulation not estimated	n = 352 with depression; age = median 28; cycles = ≥2 each	Mood decreased 3-14 days pre menses and was associated with lower HRV 0-3 days prior in clinically diagnosed women with depression
Menstrual cycle impacted mood but not sleep; mixed results for exercise	93	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n = 4 on hormonal contraception, 29 not; age = 24±3 yrs; cycles = 50 ovulatory	Participants with severe PMS versus no or low PMS walked less steps during the luteal phase (10,283±6,277) vs. menses (11,694±6,458)
	96	Clue app	Ovulation not estimated	n = 499,000; age = 21.2; yrs; cycles = not reported, over ≥12 months data per person	Menstrual cycle impacted mood, behaviour, and vital signs, while exercise and sleep behaviour were more consistent

1342

1343 LH = Luteinising Hormone, FSH = Follicle Stimulating Hormone, PMD = Premenstrual Dysphoric Disorder combining PMDD and PMS, BBT = Basal Body
1344 Temperature, RMSSD = root mean square of successive differences, SDNN = Standard Deviation of Normal-to-Normal Intervals, BMI = Body Mass Index

1345 **Table 3:** Guide to wearables, measured metrics, and associated accuracy

1346

Biometric recorded	Device	Method, sensor type, and sampling/timing of measurement, if known	Accuracy	Reference, study type, N of study
Skin temp	Oura Ring	Negative Temperature Coefficient sensor; measures every minute	Versus iButton sensor: Accuracy = 0.36°C; Precision = 0.13°C; r² >0.92 (real world), r² >0.99 (lab)	[116] In house, n=16 (company site)
			Temperature immediately after wake versus oral temperature: r= 0.563, p<0.01	[79] External, devices provided, n=22
	WHOOP 4.0	Temperature sensor during sleep	n/a	[148] (company site)

	Ava bracelet	Temperature sensor	n/a	[149] (company site)
	Apple Watch S8 onwards, all Apple Ultra	Two temperature sensors: one skin facing and one outside-facing to remove environmental bias	n/a	[150] (company site)
	Garmin (Select models only)	Temperature sensor	n/a	[151] (company site)
	Fitbit	Fitbit Sense 1/2 uses a dedicated temperature sensor. Fitbit Charge 4/5/6, Google Pixel Watch 2, Fitbit Inspire 2/3, Fitbit Luxe, and Fitbit Versa use a multi-purpose sensor	n/a	[152] (company site)
Resting heart rate	Oura Ring and Oura Ring 2.0	Blood pulse volume changes are detected through infrared PPG sensors in the ring; measured nocturnally every 10 minutes[153] (company website)	Versus ECG (bpm): r^2 = 0.996; Bias = -0.63	[122] Sponsored, n=49
			Versus ECG (bpm): r^2 = 0.998; Bias = -0.53, $p<0.001$; Range: 48-66	[123] In-house, n=10
			Versus ECG (bpm): Absolute bias = 1.8 ± 4.1; Bias = 0.1 ± 4.5; Intraclass correlation = 0.85	[121] External, n=53
	WHOOP 3.0	PPG sensor in non-wake in the primary sleep episode, every 30 seconds[154]	Versus ECG (bpm): Absolute bias = -0.7 ± 0.8; Bias = -0.3 ± 0.1; Intraclass correlation = 0.99	[121] External, n=53
	Ava bracelet	PPG sensor	Versus Polar chest strap, two electrode ECG (bpm): Bias = 7.8 ± 3.9; Pearson's r = 0.92, p=0.00; Mean absolute percentage error = 11.4%	[134] External, n=37
	Garmin Forerunner 245	PPG sensor during a 3-min period as close as practicable to the start of each sleep period, i.e., ~30–60 min prior to lights out[121]	Versus ECG (bpm): Absolute bias = 5.4 ± 12.6; Bias = 5.0 ± 12.8; Intraclass correlation = 0.41	[121] External, n=53
	Garmin Forerunner 45	PPG sensor	Versus ECG (bpm): Bias = 0.67 at rest. During two sequential ramps from rest to exercise, bias was 10.82 bpm and 3.49 bpm. At steady state, exercise bias was 0.2 bpm. No difference with skin tone except during the second ramp (underestimated, >71% had <-5bpm difference)	[126] External, n=33

	Apple Watch S6	PPG sensor during sleep[121]	Versus ECG (bpm): Absolute bias = 1.5 ± 1.5; Bias = 0.5 ± 2.1; Intraclass correlation = 0.96	[121] External, n=53
	Fitbit Charge 2	PPG sensor during rest	Versus ECG (bpm): Non-significant difference=0.09, p=0.43. Bias = 0.51 bpm when heart rate < 50 bpm; Bias = -0.63 bpm when heart rate >80 bpm	[155] External, n=17
	Huawei Band 5	PPG sensor	Limited published accuracy. Heart rate versus Polar chest strap, two electrode ECG (bpm) during elliptical exercise: r = 0.981	[156] External, Huawei provided devices, n=10
			Heart rate error range ± 10 bpm	[157] Company site
Respiratory rate	Oura Ring 2.0	Calculates rate via increase/decrease in heart rate with breath in/out	Versus ECG-calculation (respiratory rate in breaths/min): Correlation = 0.96; Mean Absolute Error = 0.71	[158] Internal, n=43
	WHOOP 2.0	Calculates median rate during sleep via increase/decrease in heart rate with breath in/out[159] (company site)	Versus respiratory inductive plethysmography (respiratory rate in breaths/min): Bias = 0.1; Percent Bias = 1.8%; Precision = 1.0; Precision Percent = 6.7%	[129] External, n=32 (21 female)
	Garmin Forerunner 245	Calculates rate via increase/decrease in heart rate with breath in/out	n/a	n/a
	Ava bracelet	Calculates rate via increase/decrease in heart rate with breath in/out	Versus chest strap (respiratory rate in breaths/min): Mean Absolute Error = 0.9; Mean Absolute Percentage Error = 6.7%	[160] External, n= 7
	Apple Watch	Accelerometer-based estimate of nocturnal breaths per minute	n/a	n/a
	Fitbit (Charge 2-4, Versa 1-2, Inspire HR)	Calculates rate via increase/decrease in heart rate with breath in/out[161]	Versus polysomnography (respiratory rate in breaths/min): Root Mean Squared Error = 0.648; Mean Absolute Error = 0.46; Mean Absolute Percentage Error = 3%; Bias = −0.24	[162] Internal, n=28
HRV	Oura Ring and Oura Ring 2.0	PPG sensor every five minutes throughout the night - reports RMSSD	Versus ECG (RMSSD in ms): r^2 = 0.980; Bias = 1.2	[122] Sponsored, n=49
			Versus ECG (RMSSD in ms): r^2 = 0.967; Bias = -0.47, p<0.001; Range = 21 to 78	[123] In-house, n=10

			Versus ECG (RMSSD in ms): Absolute accuracy = 18.9 ± 35.9; Bias = -10.2 ± 39.4; Intraclass correlation = 0.63	[121] External, n=53
			Versus ECG: RMSSD r^2 values > 0.9; Alternative HRV measures: r^2 values of SDNN (0.5), AVNN (0.8), pNN50 (0.8), LF (0.4), and HF (0.6) variable, all p<0.001	[163] External, n=35
	WHOOP 3.0	PPG sensor in non-wake in primary sleep episode every 30 seconds - reports RMSSD[154]	Versus ECG (RMSSD in ms): Absolute bias = 4.7 ± 3.6; Bias = -4.5 ± 3.9; Intraclass correlation = 0.99	[121] External, n=53
	Ava bracelet	PPG sensor[164] (company site) - reports LF/HF ratio	Versus actigraph with Polar chest strap, 2 electrode ECG (LF/HF ratio): r = -0.28, p=0.00	[134] External, n=33
	Garmin Forerunner 245	PPG sensor - reports SDRR and RMSSD	Versus ECG (RMSSD): Absolute bias = 33.1 ± 39.9; Bias = -22.4 ± 46.9; Intraclass correlation = 0.24	[121] External, n=53
	Apple Watch S6	PPG sensor - reports RMSSD	Versus ECG (RMSSD in ms): Absolute bias = 22.5 ± 19.2; Bias = −9.6 ± 28.1; Intraclass correlation = 0.67	[121] External, n=53
	Fitbit Sense	PPG sensor - reports RMSSD	n/a	n/a
	Huawei Band 5	PPG sensor - type of HRV measurement unknown	n/a	n/a
Sleep	Oura Ring 2.0	Accelerometer + temperature sensor + PPG sensor for 4-stage categorization (wake, light, deep, REM)	Versus polysomnography (sleep duration in mins): Accuracy = 0.88 ± 0.05; Sensitivity = 0.93 ± 0.05; Specificity = 0.49 ± 0.22	[165] External, n=29
			Versus polysomnography: (sleep vs wake) Accuracy = 89%; (sleep duration in mins) Bias = 1.5 ± 40.9	[121] External, n=53
	WHOOP 3.0 or 4.0	PPG sensor + accelerometer for 4-stage categorization (wake, light, deep, REM)	Versus polysomnography: (sleep vs wake) Accuracy = 86%; (sleep duration in mins) Bias = -12.2 ± 36.3	[121] External, n=53
	Garmin Forerunner 245	Accelerometer + PPG sensor + SpO2 sensor for 4-stage categorization (wake, light, deep, REM)	Versus polysomnography: (sleep vs wake) Accuracy = 89%; (sleep duration in mins) Bias = 43.8 ± 38.0	[121] External, n=53

	Ava bracelet	Accelerometer	Versus actigraphy: (sleep duration in hours) Mean Absolute Percent Error = 8.5%; Pearson's r = 0.73, p=0.00; Bias = 0.18 ± 0.88	[134] External, n=33
	Apple Watch S6	PPG sensor in 5 min epochs; 3-stage categorization (wake, light, deep)	Versus polysonography: (sleep vs wake) Accuracy = 88%; (sleep duration in mins) Bias = 39.5 ± 41.5	[121] External, n=53
	Fitbit (Alta[133]; Charge[165]; Non-sleep-staging models = Charge HR, Flex, Alta, One, Ultra, Classic; Sleep-staging models = Surge, Alta HR, Charge 2, Versa)	PPG sensor + accelerometer for 4-stage categorization (wake, light, deep, REM)[166]	Versus actigraphy: (sleep duration in minutes) Intraclass correlation = 0.84; Mean Absolute Error = 56	[133] External, n=30
			Versus polysomnography: (sleep duration in minutes) Accuracy = 0.84 ± 0.07; Sensitivity = 0.89 ± 0.09; Specificity = 0.49 ± 0.18	[165] External, n=27
			Older sleep-staging models using movement only: Versus polysonography: (sleep duration in minutes) Bias = 7-67 mins; (wake duration in minutes) Bias = 6-44; (sleep efficiency) Bias = 2-15%; No difference in sleep onset latency. Sensitivity = 0.87-0.99; Specificity = 0.1-0.52 *Newer sleep-staging models using HRV and movement;* Versus polysonography: Newer models show no difference for sleep duration, wake after sleep onset, but underestimated sleep onset latency. Sensitivity = 0.95-0.96; Specificity = 0.58-0.69	[167] Systematic review with 8 papers with quantitative data, n=7 to 63
	Huawei Band GT	Uses accelerometry, HR, HRV for 4-stage categorization (wake, light, deep, REM)[168] (company site)	Versus actigraphy (sleep time assessment): Intraclass correlation: 0.25; Mean Absolute Percentage Error = 23.29%	[169] External, n=102

1347

1348 PPG= photoplethysmography, ECG = electrocardiogram, RMSSD = root mean square of successive differences, SDNN = Standard Deviation of Normal-to-Normal
1349 Intervals, AVNN=Average of the Normal-to-Normal (NN) intervals, pNN50 = percentage of Normal-to-Normal (NN) intervals that differ by more than 50
1350 milliseconds from the preceding interval, LF = low frequency, HF=high frequency, SDRR = standard deviation between consecutive R-wav

1351

1352